Identification

Name
Irinotecan
Accession Number
DB00762  (APRD00579)
Type
Small Molecule
Groups
Approved, Investigational
Description

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Structure
Thumb
Synonyms
  • Biotecan
  • Camptothecin-11
Product Ingredients
IngredientUNIICASInChI Key
Irinotecan hydrochloride06X131E4OE100286-90-6GURKHSYORGJETM-WAQYZQTGSA-N
Irinotecan hydrochloride hydrate042LAQ1IIS136572-09-3OHNBIIZWIUBGTK-NYPSMHOZSA-N
Irinotecan sucrosofateOL741S3N8B1361317-83-0PMZSPINGJVBHAT-DJBCQDJXSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CamptosarInjection, solution20 mg/mLIntravenousPharmacia & Upjohn Inc1996-06-14Not applicableUs
CamptosarInjection, solution20 mg/mLIntravenousPharmacia & Upjohn Inc1996-06-14Not applicableUs
Camptosar InjectionSolution20 mgIntravenousPfizer1997-08-27Not applicableCanada
IrinotecanSolution20 mgIntravenousPfizer2014-03-07Not applicableCanada
Irinotecan for InjectionSolution20 mgIntravenousTeva2008-10-31Not applicableCanada
Irinotecan Hydrochloride InjectionSolution20 mgIntravenousTeligent Ou2015-05-28Not applicableCanada
Irinotecan Hydrochloride Injection USPSolution20 mgIntravenousPfizer2006-02-01Not applicableCanada
Irinotecan Hydrochloride Injection, USPSolution20 mgIntravenousQilu Pharmaceuticals Co. LtdNot applicableNot applicableCanada
Irinotecan Hydrochloride Trihydrate for InjectionSolution20 mgIntravenousAccord Healthcare Limited2013-05-06Not applicableCanada
Irinotecan Hydrochloride Trihydrate for InjectionSolution20 mgIntravenousFresenius Kabi2011-05-27Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Irinotecan HydrochlorideInjection20 mg/mLIntravenousWest Ward Pharmaceutical2010-12-20Not applicableUs
Irinotecan HydrochlorideInjection20 mg/mLIntravenousHeritage2012-06-20Not applicableUs
Irinotecan HydrochlorideInjection, solution20 mg/mLIntravenousHospira, Inc.2008-02-27Not applicableUs
Irinotecan HydrochlorideInjection20 mg/mLIntravenousAreva Pharmaceuticals,Inc.2008-02-20Not applicableUs
Irinotecan HydrochlorideInjection20 mg/mLIntravenousNorth Star Rx Llc2017-06-15Not applicableUs
Irinotecan HydrochlorideInjection, solution100 mg/5mLIntravenousTeva Parenteral Medicines, Inc.2008-02-27Not applicableUs
Irinotecan HydrochlorideInjection40 mg/2mLIntravenousSun Pharma Global FZE2008-04-212017-01-28Us
Irinotecan HydrochlorideInjection40 mg/2mLIntravenousIngenus Pharmaceuticals Llc2017-06-05Not applicableUs
Irinotecan HydrochlorideInjection, solution20 mg/mLIntravenousApotex Corporation2017-11-30Not applicableUs
Irinotecan HydrochlorideInjection20 mg/mLIntravenousBlue Point Laboratories2008-02-20Not applicableUs
International/Other Brands
Campto (YakultHonsha Co. Ltd.)
Categories
UNII
7673326042
CAS number
97682-44-5
Weight
Average: 586.678
Monoisotopic: 586.279134968
Chemical Formula
C33H38N4O6
InChI Key
UWKQSNNFCGGAFS-XIFFEERXSA-N
InChI
InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
IUPAC Name
(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl 4-(piperidin-1-yl)piperidine-1-carboxylate
SMILES
CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=C1C=C(OC(=O)N1CCC(CC1)N1CCCCC1)C=C2

Pharmacology

Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions
Pharmacodynamics

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is a semisynthetic derivative of camptothecin. Camptothecins interact specifically with topoisomerase I, an enzyme in the cell nucleus that regulates DNA topology and facilitates nuclear processes such as DNA replication, recombination, and repair. During these processes, topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks, allowing single DNA strands to pass through the break. The 3'-DNA terminus of the broken DNA strands bind covalently with the topoisomerase enzyme to form a catalytic intermediate called a cleavable complex. After the DNA is sufficiently relaxed and the strand passage reaction is complete, DNA topoisomerase reattaches the broken DNA strands to form the chemically unaltered topoisomers that allow transcription to proceed. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. The precise contribution of SN-38 to the activity of irinotecan in humans is not known. Irinotecan is cell cycle phase-specific (S-phase).

Mechanism of action

Irinotecan inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex. The formation of this ternary complex interferes with the moving replication fork, which induces replication arrest and lethal double-stranded breaks in DNA. As a result, DNA damage is not efficiently repaired and apoptosis (programmed cell death) occurs.

TargetActionsOrganism
ADNA topoisomerase 1
inhibitor
Human
ADNA topoisomerase I, mitochondrial
inhibitor
Human
Absorption

The maximum plasma concentration (Cmax) when a dose of 125 mg/m^2 is given to patients with solid tumours is 1660 ng/mL. The AUC (0-24) is 10,200 ng·h/mL. The Cmax when a dose of 340 mg/m^2 is given to patients with solid tumours is 3392 ng/mL. The AUC (0-24) is 20,604 ng·h/mL.

Volume of distribution

The volume of distribution of terminal elimination phase is 110 L/m^2 when a dose of 125 mg/m^2 is given to patients with solid tumours. The volume of distribution of terminal elimination phase is 234 L/m^2 when a dose of 340 mg/m^2 is given to patients with solid tumours.

Protein binding

30%-68% protein bound, mainly to albumin.

Metabolism

Hepatic. The metabolic conversion of irinotecan to the active metabolite SN-38 is mediated by carboxylesterase enzymes and primarily occurs in the liver. SN-38 is subsequently conjugated predominantly by the enzyme UDP-glucuronosyl transferase 1A1 (UGT1A1) to form a glucuronide metabolite.

Route of elimination

The cumulative biliary and urinary excretion of irinotecan and its metabolites (SN-38 and SN-38 glucuronide) over a period of 48 hours following administration of irinotecan in two patients ranged from approximately 25% (100 mg/m2) to 50% (300 mg/m2).

Half life

The half life of irinotecan is about 6 - 12 hours. The terminal elimination half-life of the active metabolite, SN-38 is 10 - 20 hours.

Clearance
  • 13.3 L/h/m^2 [Dose of 125 mg/m^2, patients with solid tumours]
  • 13.9 L/h/m^2 [Dose of 340 mg/m^2, patients with solid tumours]
Toxicity

Gastrointestinal complications, such as nausea, vomiting, abdominal cramping, diarrhea, and infection.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Irinotecan Action PathwayDrug action
Irinotecan Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Solute carrier organic anion transporter family member 1B1SLCO1B1*15(C;C) / (C;T)C Allele / G AlleleDirectly Studied EffectPatients with this genotype have reduced transport of the active metabolite of irinotecan resulting in increased plasma concentrations.Details
UDP-glucuronosyltransferase 1-1UGT1A1*28 or UGT1A 7/7Not Availableextra TA in promoterADR Directly StudiedThe presence of this genotype in UGT1A1 may indicate an increased risk of bone marrow toxicity when treated with irinotecan.Details
UDP-glucuronosyltransferase 1-7UGT1A7*2/*2(G;G) / (G;T) / (A;A) / (A;C) / (A;A) / (A;G)G allele / A allele  … show all ADR Directly StudiedThe presence of this genotype in UGT1A1 may indicate an increased risk of bone marrow toxicity when treated with irinotecan.Details
UDP-glucuronosyltransferase 1-1UGT1A1*93(A;A) / (A;G)A AlleleADR Directly StudiedThe presence of this genotype in UGT1A1 may indicate an increased risk of bone marrow toxicity when treated with irinotecan.Details
UDP-glucuronosyltransferase 1-1UGT1A1*28Not Availableextra TA in promoter, homozygousADR Directly StudiedPatients who carry this genotype in UGT1A1 are at increased risk for neutropenia following initiation of irinotecan treatment.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Irinotecan is combined with 2-Methoxyethanol.Experimental
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Irinotecan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.Investigational
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Irinotecan.Approved
AbemaciclibThe serum concentration of Irinotecan can be increased when it is combined with Abemaciclib.Approved, Investigational
AbetimusThe risk or severity of adverse effects can be increased when Irinotecan is combined with Abetimus.Investigational
AcetaminophenThe serum concentration of Irinotecan can be increased when it is combined with Acetaminophen.Approved
ActeosideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Acteoside.Investigational
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Irinotecan.Approved
AdenineThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Adenine.Approved, Nutraceutical
AfatinibThe serum concentration of Irinotecan can be increased when it is combined with Afatinib.Approved
AfelimomabThe risk or severity of adverse effects can be increased when Irinotecan is combined with Afelimomab.Investigational
AlbendazoleThe serum concentration of Irinotecan can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Alclometasone.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Irinotecan is combined with Aldesleukin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Aldosterone.Experimental, Investigational
AlectinibThe serum concentration of Irinotecan can be increased when it is combined with Alectinib.Approved, Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Irinotecan is combined with Alefacept.Approved, Investigational, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Irinotecan.Approved, Investigational
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Irinotecan.Approved
AmbrisentanThe excretion of Ambrisentan can be decreased when combined with Irinotecan.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Amcinonide.Approved
AmiodaroneThe serum concentration of Irinotecan can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineThe serum concentration of Irinotecan can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Irinotecan can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe serum concentration of Irinotecan can be increased when it is combined with Amoxapine.Approved
AmprenavirThe metabolism of Irinotecan can be decreased when combined with Amprenavir.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Irinotecan.Approved, Investigational
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Irinotecan.Approved
AnnamycinThe serum concentration of Irinotecan can be increased when it is combined with Annamycin.Investigational
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Irinotecan.Approved
Anthrax vaccineThe risk or severity of infection can be increased when Anthrax vaccine is combined with Irinotecan.Approved
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Irinotecan.Approved
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Irinotecan.Approved, Investigational
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Irinotecan.Approved
ApalutamideThe serum concentration of Irinotecan can be decreased when it is combined with Apalutamide.Approved, Investigational
ApremilastThe risk or severity of adverse effects can be increased when Irinotecan is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Irinotecan can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Arsenic trioxide.Approved, Investigational
AstemizoleThe serum concentration of Irinotecan can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe excretion of Asunaprevir can be decreased when combined with Irinotecan.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Irinotecan can be increased when it is combined with Atazanavir.Approved, Investigational
AtorvastatinThe serum concentration of Irinotecan can be increased when it is combined with Atorvastatin.Approved
AtrasentanThe excretion of Atrasentan can be decreased when combined with Irinotecan.Investigational
AvatrombopagThe serum concentration of Irinotecan can be increased when it is combined with Avatrombopag.Approved, Investigational
AxitinibThe excretion of Axitinib can be decreased when combined with Irinotecan.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Azacitidine.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Irinotecan.Approved
AzelastineThe serum concentration of Irinotecan can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Irinotecan can be increased when it is combined with Azithromycin.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Irinotecan.Approved, Investigational
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Irinotecan.Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Irinotecan.Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Irinotecan.Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Irinotecan.Approved
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Irinotecan.Approved
Bafilomycin A1The serum concentration of Irinotecan can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Irinotecan can be increased when it is combined with Bafilomycin B1.Experimental
BaricitinibThe serum concentration of Irinotecan can be increased when it is combined with Baricitinib.Approved, Investigational
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Irinotecan.Approved, Investigational
BCG vaccineThe risk or severity of infection can be increased when BCG vaccine is combined with Irinotecan.Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Irinotecan.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Beclomethasone dipropionate.Approved, Investigational
BegelomabThe risk or severity of adverse effects can be increased when Irinotecan is combined with Begelomab.Experimental, Investigational
BelataceptThe risk or severity of adverse effects can be increased when Belatacept is combined with Irinotecan.Approved, Investigational
BelimumabThe risk or severity of adverse effects can be increased when Belimumab is combined with Irinotecan.Approved
BelinostatThe risk or severity of adverse effects can be increased when Irinotecan is combined with Belinostat.Approved, Investigational
BendamustineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Bendamustine.Approved, Investigational
BenzquinamideThe serum concentration of Irinotecan can be increased when it is combined with Benzquinamide.Withdrawn
Benzyl alcoholThe serum concentration of Irinotecan can be increased when it is combined with Benzyl alcohol.Approved
BenzylpenicillinThe excretion of Benzylpenicillin can be decreased when combined with Irinotecan.Approved, Vet Approved
BepridilThe serum concentration of Irinotecan can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Irinotecan.Approved, Vet Approved
BevacizumabThe risk or severity of adverse effects can be increased when Irinotecan is combined with Bevacizumab.Approved, Investigational
BexaroteneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Bexarotene.Approved, Investigational
BicalutamideThe serum concentration of Irinotecan can be increased when it is combined with Bicalutamide.Approved
Biricodar dicitrateThe serum concentration of Irinotecan can be increased when it is combined with Biricodar dicitrate.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with Irinotecan.Approved, Investigational
BlinatumomabThe risk or severity of adverse effects can be increased when Irinotecan is combined with Blinatumomab.Approved, Investigational
BoceprevirThe serum concentration of Irinotecan can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Irinotecan is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Irinotecan can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe risk or severity of adverse effects can be increased when Irinotecan is combined with Bosutinib.Approved
Brefeldin AThe serum concentration of Irinotecan can be increased when it is combined with Brefeldin A.Experimental
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Irinotecan is combined with Brentuximab vedotin.Approved, Investigational
BriakinumabThe risk or severity of adverse effects can be increased when Irinotecan is combined with Briakinumab.Investigational
BrigatinibThe serum concentration of Irinotecan can be increased when it is combined with Brigatinib.Approved, Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Irinotecan is combined with Brodalumab.Approved, Investigational
BromocriptineThe serum concentration of Irinotecan can be increased when it is combined with Bromocriptine.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Budesonide.Approved
BuprenorphineThe serum concentration of Irinotecan can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Irinotecan can be increased when it is combined with Buspirone.Approved, Investigational
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Irinotecan.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Irinotecan is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Irinotecan can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Irinotecan can be increased when it is combined with Canagliflozin.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Canakinumab is combined with Irinotecan.Approved, Investigational
CannabidiolThe serum concentration of Irinotecan can be increased when it is combined with Cannabidiol.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Irinotecan can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Irinotecan can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarboplatinThe risk or severity of adverse effects can be increased when Irinotecan is combined with Carboplatin.Approved
CarfilzomibThe risk or severity of adverse effects can be increased when Irinotecan is combined with Carfilzomib.Approved, Investigational
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Irinotecan.Approved, Investigational
CarvedilolThe serum concentration of Irinotecan can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe excretion of Caspofungin can be decreased when combined with Irinotecan.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Castanospermine.Experimental
CefoperazoneThe serum concentration of Irinotecan can be increased when it is combined with Cefoperazone.Approved, Investigational
CeftriaxoneThe serum concentration of Irinotecan can be increased when it is combined with Ceftriaxone.Approved
CeritinibThe serum concentration of Irinotecan can be increased when it is combined with Ceritinib.Approved
CerivastatinThe excretion of Cerivastatin can be decreased when combined with Irinotecan.Approved, Withdrawn
Certolizumab pegolThe risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Irinotecan.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Irinotecan.Approved
ChloramphenicolThe risk or severity of adverse effects can be increased when Irinotecan is combined with Chloramphenicol.Approved, Vet Approved
ChloroformThe serum concentration of Irinotecan can be increased when it is combined with Chloroform.Vet Approved
ChlorpromazineThe serum concentration of Irinotecan can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe serum concentration of Irinotecan can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CholecystokininThe excretion of Cholecystokinin can be decreased when combined with Irinotecan.Approved, Investigational
Cholic AcidThe excretion of Cholic Acid can be decreased when combined with Irinotecan.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Ciclesonide.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Irinotecan.Approved
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Irinotecan.Approved, Investigational
ClarithromycinThe serum concentration of Irinotecan can be increased when it is combined with Clarithromycin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Irinotecan is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Clocortolone.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Irinotecan.Approved, Investigational
ClofazimineThe serum concentration of Irinotecan can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Irinotecan can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
CloprednolThe risk or severity of adverse effects can be increased when Irinotecan is combined with Cloprednol.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Irinotecan.Approved
ClotrimazoleThe serum concentration of Irinotecan can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Clozapine.Approved
CobicistatThe serum concentration of Irinotecan can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Irinotecan can be increased when it is combined with Colchicine.Approved
Concanamycin AThe serum concentration of Irinotecan can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Irinotecan.Approved, Investigational
Conjugated estrogensThe excretion of Conjugated estrogens can be decreased when combined with Irinotecan.Approved
CorticotropinThe risk or severity of adverse effects can be increased when Irinotecan is combined with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Cortisone acetate.Approved, Investigational
CortivazolThe risk or severity of adverse effects can be increased when Irinotecan is combined with Cortivazol.Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Irinotecan.Approved
CrizotinibThe serum concentration of Irinotecan can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Irinotecan can be increased when it is combined with Curcumin.Approved, Investigational
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Irinotecan.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Irinotecan.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Irinotecan.Approved, Investigational
DabrafenibThe serum concentration of Irinotecan can be decreased when it is combined with Dabrafenib.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Dacarbazine.Approved, Investigational
DaclatasvirThe serum concentration of Irinotecan can be increased when it is combined with Daclatasvir.Approved, Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Daclizumab is combined with Irinotecan.Investigational, Withdrawn
DactinomycinThe risk or severity of adverse effects can be increased when Irinotecan is combined with Dactinomycin.Approved, Investigational
DaidzinThe serum concentration of Irinotecan can be increased when it is combined with Daidzin.Experimental
DanazolThe metabolism of Irinotecan can be decreased when combined with Danazol.Approved
DarunavirThe serum concentration of Irinotecan can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Irinotecan can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Irinotecan can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Irinotecan.Approved
DecitabineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Irinotecan can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Irinotecan is combined with Deflazacort.Approved, Investigational
DelavirdineThe serum concentration of Irinotecan can be increased when it is combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Irinotecan is combined with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Irinotecan is combined with Deoxyspergualin.Investigational
DesipramineThe serum concentration of Irinotecan can be increased when it is combined with Desipramine.Approved, Investigational
DesmethylsertralineThe serum concentration of Irinotecan can be increased when it is combined with Desmethylsertraline.Experimental
DesonideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Desoximetasone.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Dexamethasone isonicotinate.Vet Approved
DexniguldipineThe serum concentration of Irinotecan can be increased when it is combined with Dexniguldipine.Experimental
DexrazoxaneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Dexrazoxane.Approved, Withdrawn
DexverapamilThe serum concentration of Irinotecan can be increased when it is combined with Dexverapamil.Experimental
Diethyl etherThe serum concentration of Irinotecan can be increased when it is combined with Diethyl ether.Experimental
DiethylstilbestrolThe serum concentration of Irinotecan can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DiflorasoneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Diflorasone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Difluprednate.Approved
DihydroergotamineThe serum concentration of Irinotecan can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe serum concentration of Irinotecan can be increased when it is combined with Diltiazem.Approved, Investigational
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Dimethyl fumarate.Approved, Investigational
DinoprostoneThe excretion of Dinoprostone can be decreased when combined with Irinotecan.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Irinotecan is combined with Dinutuximab.Approved, Investigational
DipyridamoleThe serum concentration of Irinotecan can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Irinotecan is combined with Docetaxel.Approved, Investigational
DofequidarThe serum concentration of Irinotecan can be increased when it is combined with Dofequidar.Experimental, Investigational
DovitinibThe serum concentration of Irinotecan can be increased when it is combined with Dovitinib.Investigational
DoxazosinThe serum concentration of Irinotecan can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Irinotecan can be increased when it is combined with Doxepin.Approved, Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Doxifluridine.Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Irinotecan is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Irinotecan can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Irinotecan can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Irinotecan can be increased when it is combined with Dronedarone.Approved
DuloxetineThe serum concentration of Irinotecan can be increased when it is combined with Duloxetine.Approved
EconazoleThe serum concentration of Irinotecan can be increased when it is combined with Econazole.Approved
EculizumabThe risk or severity of adverse effects can be increased when Eculizumab is combined with Irinotecan.Approved, Investigational
EfalizumabThe risk or severity of adverse effects can be increased when Irinotecan is combined with Efalizumab.Approved, Investigational
EfavirenzThe serum concentration of Irinotecan can be increased when it is combined with Efavirenz.Approved, Investigational
ElacridarThe serum concentration of Irinotecan can be increased when it is combined with Elacridar.Investigational
ElagolixThe excretion of Elagolix can be decreased when combined with Irinotecan.Approved, Investigational
EltrombopagThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Eltrombopag.Approved
EluxadolineThe excretion of Eluxadoline can be decreased when combined with Irinotecan.Approved, Investigational
EmopamilThe serum concentration of Irinotecan can be increased when it is combined with Emopamil.Experimental
EnalaprilThe excretion of Enalapril can be decreased when combined with Irinotecan.Approved, Vet Approved
EnasidenibThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Enasidenib.Approved, Investigational
EnzalutamideThe serum concentration of Irinotecan can be decreased when it is combined with Enzalutamide.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Irinotecan.Approved
ErgonovineThe serum concentration of Irinotecan can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Irinotecan can be increased when it is combined with Ergotamine.Approved
EribulinThe risk or severity of adverse effects can be increased when Irinotecan is combined with Eribulin.Approved, Investigational
ErlotinibThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Erlotinib.Approved, Investigational
ErtugliflozinThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Ertugliflozin.Approved, Investigational
ErythromycinThe serum concentration of Irinotecan can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EsomeprazoleThe serum concentration of Irinotecan can be increased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Irinotecan can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Irinotecan can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Irinotecan can be increased when it is combined with Estradiol benzoate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Irinotecan can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Irinotecan can be increased when it is combined with Estradiol dienanthate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Irinotecan can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EstramustineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Estramustine.Approved, Investigational
EstroneThe serum concentration of Irinotecan can be increased when it is combined with Estrone.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Irinotecan.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Irinotecan can be decreased when it is combined with Ethinyl Estradiol.Approved
EtoposideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Etoposide.Approved
EtravirineThe serum concentration of Irinotecan can be decreased when it is combined with Etravirine.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Irinotecan.Approved
EzetimibeThe serum concentration of Irinotecan can be increased when it is combined with Ezetimibe.Approved
FelodipineThe serum concentration of Irinotecan can be increased when it is combined with Felodipine.Approved, Investigational
FenofibrateThe serum concentration of Irinotecan can be increased when it is combined with Fenofibrate.Approved
FentanylThe serum concentration of Irinotecan can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe excretion of Fexofenadine can be decreased when combined with Irinotecan.Approved, Investigational
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with Irinotecan.Approved, Investigational
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Irinotecan.Approved
FlucloroloneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Fluclorolone.Experimental
FluconazoleThe serum concentration of Irinotecan can be increased when it is combined with Fluconazole.Approved, Investigational
FlucytosineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Flucytosine.Approved, Investigational
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Irinotecan.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Irinotecan.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Flunisolide.Approved, Investigational
FlunitrazepamThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Flunitrazepam.Approved, Illicit
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Fluocinonide.Approved, Investigational
FluocortinThe risk or severity of adverse effects can be increased when Irinotecan is combined with Fluocortin.Experimental
FluocortoloneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Fluorometholone.Approved, Investigational
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Irinotecan.Approved
FluoxetineThe serum concentration of Irinotecan can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Irinotecan can be increased when it is combined with Flupentixol.Approved, Investigational, Withdrawn
FluperoloneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Fluperolone.Experimental
FluphenazineThe serum concentration of Irinotecan can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Flurandrenolide.Approved
FlurazepamThe serum concentration of Irinotecan can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FlurbiprofenThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Fluticasone propionate.Approved
FluvastatinThe excretion of Fluvastatin can be decreased when combined with Irinotecan.Approved
FluvoxamineThe serum concentration of Irinotecan can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormocortalThe risk or severity of adverse effects can be increased when Irinotecan is combined with Formocortal.Experimental
FosamprenavirThe metabolism of Irinotecan can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Irinotecan can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Irinotecan can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FostamatinibThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Fostamatinib.Approved, Investigational
Fusidic AcidThe serum concentration of Irinotecan can be increased when it is combined with Fusidic Acid.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Irinotecan.Investigational
Gadoxetic acidThe excretion of Gadoxetic acid can be decreased when combined with Irinotecan.Approved
Gallium nitrateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Gallium nitrate.Approved, Investigational
GallopamilThe serum concentration of Irinotecan can be increased when it is combined with Gallopamil.Investigational
GefitinibThe serum concentration of Irinotecan can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Irinotecan.Approved
GemfibrozilThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Gemfibrozil.Approved
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Irinotecan.Approved, Investigational
GenisteinThe serum concentration of Irinotecan can be increased when it is combined with Genistein.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Irinotecan.Investigational
GimatecanThe excretion of Gimatecan can be decreased when combined with Irinotecan.Investigational
GlatiramerThe risk or severity of adverse effects can be increased when Glatiramer is combined with Irinotecan.Approved, Investigational
GlecaprevirThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Glecaprevir.Approved, Investigational
GlyburideThe serum concentration of Irinotecan can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Irinotecan can be increased when it is combined with Glycerin.Approved, Investigational
GolimumabThe risk or severity of adverse effects can be increased when Golimumab is combined with Irinotecan.Approved
Gramicidin DThe serum concentration of Irinotecan can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe excretion of Grazoprevir can be decreased when combined with Irinotecan.Approved
GusperimusThe risk or severity of adverse effects can be increased when Gusperimus is combined with Irinotecan.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Halcinonide.Approved, Investigational, Withdrawn
HalometasoneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Halometasone.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Irinotecan.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Irinotecan.Approved, Withdrawn
HesperetinThe serum concentration of Irinotecan can be increased when it is combined with Hesperetin.Approved
HM-30181The serum concentration of Irinotecan can be increased when it is combined with HM-30181.Experimental
Human rabies virus immune globulinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Irinotecan.Approved
HycanthoneThe serum concentration of Irinotecan can be increased when it is combined with Hycanthone.Approved, Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Irinotecan.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Hydrocortisone aceponate.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Hydrocortisone butyrate.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Hydrocortisone probutate.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Hydrocortisone succinate.Approved
Hydrocortisone valerateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Hydrocortisone valerate.Approved, Vet Approved
HydroxychloroquineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Hydroxychloroquine.Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Irinotecan is combined with Hydroxyurea.Approved
HypericinThe risk or severity of adverse effects can be increased when Irinotecan is combined with Hypericin.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Irinotecan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Irinotecan is combined with Ibrutinib.Approved
IbuprofenThe serum concentration of Irinotecan can be increased when it is combined with Ibuprofen.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Irinotecan is combined with Idarubicin.Approved
IdelalisibThe serum concentration of Irinotecan can be increased when it is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Ifosfamide.Approved
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Irinotecan.Approved
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with Irinotecan.Approved, Investigational
IndinavirThe serum concentration of Irinotecan can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Irinotecan can be increased when it is combined with Indomethacin.Approved, Investigational
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Irinotecan.Approved
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Irinotecan.Investigational
Interferon alfa-n3The risk or severity of adverse effects can be increased when Irinotecan is combined with Interferon alfa-n3.Approved, Investigational
Interferon alfacon-1The risk or severity of adverse effects can be increased when Irinotecan is combined with Interferon alfacon-1.Approved, Investigational
IsavuconazoleThe serum concentration of Irinotecan can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Irinotecan can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Irinotecan can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe serum concentration of Irinotecan can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Irinotecan can be increased when it is combined with Itraconazole.Approved, Investigational
IvermectinThe serum concentration of Irinotecan can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Irinotecan can be increased when it is combined with Ivosidenib.Approved, Investigational
IxabepiloneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Ixabepilone.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Irinotecan.Approved
KetoconazoleThe serum concentration of Irinotecan can be increased when it is combined with Ketoconazole.Approved, Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Irinotecan.Approved, Investigational, Nutraceutical
LamotrigineThe serum concentration of Irinotecan can be decreased when it is combined with Lamotrigine.Approved, Investigational
LaniquidarThe serum concentration of Irinotecan can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe serum concentration of Irinotecan can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Irinotecan can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Irinotecan can be increased when it is combined with Ledipasvir.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Irinotecan.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Irinotecan.Approved
LetermovirThe serum concentration of Irinotecan can be increased when it is combined with Letermovir.Approved, Investigational
LevofloxacinThe serum concentration of Irinotecan can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomenolThe excretion of Levomenol can be decreased when combined with Irinotecan.Approved, Experimental
LevosalbutamolThe excretion of Levosalbutamol can be decreased when combined with Irinotecan.Approved, Investigational
LevothyroxineThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Levothyroxine.Approved
LidocaineThe serum concentration of Irinotecan can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Irinotecan can be increased when it is combined with Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Irinotecan is combined with Linezolid.Approved, Investigational
LiothyronineThe excretion of Liothyronine can be decreased when combined with Irinotecan.Approved, Vet Approved
LiotrixThe excretion of Liotrix can be decreased when combined with Irinotecan.Approved
LipegfilgrastimIrinotecan may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
LomerizineThe serum concentration of Irinotecan can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Irinotecan can be increased when it is combined with Lomitapide.Approved, Investigational
LomustineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Lomustine.Approved, Investigational
LonafarnibThe serum concentration of Irinotecan can be increased when it is combined with Lonafarnib.Investigational
LoperamideThe serum concentration of Irinotecan can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Irinotecan can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Irinotecan can be increased when it is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Irinotecan can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Irinotecan can be increased when it is combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Irinotecan is combined with Loteprednol.Approved
LovastatinThe serum concentration of Irinotecan can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe serum concentration of Irinotecan can be increased when it is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Irinotecan can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Irinotecan can be decreased when it is combined with Lumacaftor.Approved
LusutrombopagThe serum concentration of Irinotecan can be increased when it is combined with Lusutrombopag.Approved, Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Mechlorethamine.Approved, Investigational
Medical CannabisThe serum concentration of Irinotecan can be increased when it is combined with Medical Cannabis.Experimental, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Medrysone.Approved
MefloquineThe serum concentration of Irinotecan can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Irinotecan can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Irinotecan is combined with Melengestrol.Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Irinotecan.Approved
MepolizumabThe risk or severity of adverse effects can be increased when Mepolizumab is combined with Irinotecan.Approved, Investigational
MeprednisoneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Meprednisone.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Irinotecan.Approved
MetamizoleThe risk or severity of myelosuppression can be increased when Metamizole is combined with Irinotecan.Approved, Investigational, Withdrawn
MethadoneThe serum concentration of Irinotecan can be increased when it is combined with Methadone.Approved
MethimazoleThe risk or severity of adverse effects can be increased when Irinotecan is combined with Methimazole.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Irinotecan.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Methylprednisolone.Approved, Vet Approved
MetronidazoleThe serum concentration of Irinotecan can be increased when it is combined with Metronidazole.Approved
MibefradilThe serum concentration of Irinotecan can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Irinotecan can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Irinotecan can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Irinotecan can be increased when it is combined with Mifepristone.Approved, Investigational
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Irinotecan.Approved
MitotaneThe serum concentration of Irinotecan can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Mizoribine.Investigational
ModafinilThe serum concentration of Irinotecan can be decreased when it is combined with Modafinil.Approved, Investigational
MometasoneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Mometasone.Approved, Vet Approved
Mometasone furoateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Mometasone furoate.Approved, Vet Approved
MonensinThe serum concentration of Irinotecan can be increased when it is combined with Monensin.Vet Approved
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with Irinotecan.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Irinotecan.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Irinotecan.Approved
NabiximolsThe serum concentration of Irinotecan can be increased when it is combined with Nabiximols.Approved, Investigational
NafcillinThe serum concentration of Irinotecan can be decreased when it is combined with Nafcillin.Approved, Investigational
NaloxoneThe serum concentration of Irinotecan can be increased when it is combined with Naloxone.Approved, Vet Approved
NaringeninThe serum concentration of Irinotecan can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Natalizumab is combined with Irinotecan.Approved, Investigational
NefazodoneThe serum concentration of Irinotecan can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Nelarabine.Approved, Investigational
NelfinavirThe serum concentration of Irinotecan can be increased when it is combined with Nelfinavir.Approved
NeratinibThe serum concentration of Irinotecan can be increased when it is combined with Neratinib.Approved, Investigational
NetupitantThe serum concentration of Irinotecan can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Irinotecan can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Irinotecan can be increased when it is combined with Nicardipine.Approved, Investigational
NigericinThe serum concentration of Irinotecan can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Irinotecan can be increased when it is combined with Niguldipine.Experimental
NilotinibThe serum concentration of Irinotecan can be increased when it is combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Irinotecan can be increased when it is combined with Nimodipine.Approved, Investigational
NisoldipineThe serum concentration of Irinotecan can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Irinotecan can be increased when it is combined with Nitrendipine.Approved, Investigational
NovobiocinThe serum concentration of Irinotecan can be increased when it is combined with Novobiocin.Approved, Investigational, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Irinotecan is combined with Obinutuzumab.Approved, Investigational
OcrelizumabThe risk or severity of adverse effects can be increased when Irinotecan is combined with Ocrelizumab.Approved, Investigational
OlaparibThe risk or severity of adverse effects can be increased when Irinotecan is combined with Olaparib.Approved
OlmesartanThe excretion of Olmesartan can be decreased when combined with Irinotecan.Approved, Investigational
OmeprazoleThe serum concentration of Irinotecan can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
ONT-093The serum concentration of Irinotecan can be increased when it is combined with ONT-093.Investigational
OsimertinibThe serum concentration of Irinotecan can be increased when it is combined with Osimertinib.Approved
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Irinotecan.Approved, Investigational
OxcarbazepineThe serum concentration of Irinotecan can be decreased when it is combined with Oxcarbazepine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Irinotecan is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Irinotecan can be increased when it is combined with Palbociclib.Approved, Investigational
PaliferminThe therapeutic efficacy of Palifermin can be decreased when used in combination with Irinotecan.Approved
PaliperidoneThe serum concentration of Irinotecan can be increased when it is combined with Paliperidone.Approved
PanobinostatThe risk or severity of adverse effects can be increased when Irinotecan is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Irinotecan can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Paramethasone.Approved
ParitaprevirThe serum concentration of Irinotecan can be increased when it is combined with Paritaprevir.Approved, Investigational
ParoxetineThe serum concentration of Irinotecan can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Pazopanib.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Pegaspargase is combined with Irinotecan.Approved, Investigational
Peginterferon alfa-2aThe risk or severity of adverse effects can be increased when Irinotecan is combined with Peginterferon alfa-2a.Approved, Investigational
Peginterferon alfa-2bThe risk or severity of adverse effects can be increased when Irinotecan is combined with Peginterferon alfa-2b.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Irinotecan.Approved, Investigational
PenicillamineThe excretion of Penicillamine can be decreased when combined with Irinotecan.Approved
PentazocineThe serum concentration of Irinotecan can be increased when it is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe serum concentration of Irinotecan can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Irinotecan.Approved, Investigational
PethidineThe serum concentration of Irinotecan can be increased when it is combined with Pethidine.Approved
PhenobarbitalThe serum concentration of Irinotecan can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenytoinThe serum concentration of Irinotecan can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Pibrentasvir.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Irinotecan is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Irinotecan can be increased when it is combined with Pimozide.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Irinotecan is combined with Pirarubicin.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Pirfenidone.Approved, Investigational
PitavastatinThe excretion of Pitavastatin can be decreased when combined with Irinotecan.Approved
PitolisantThe serum concentration of Irinotecan can be decreased when it is combined with Pitolisant.Approved, Investigational
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Irinotecan.Approved
PonatinibThe risk or severity of adverse effects can be increased when Irinotecan is combined with Ponatinib.Approved, Investigational
PosaconazoleThe serum concentration of Irinotecan can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Pralatrexate.Approved, Investigational
PravastatinThe serum concentration of Irinotecan can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Irinotecan can be increased when it is combined with Prazosin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Irinotecan.Approved, Vet Approved
PrednylideneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Prednylidene.Experimental
PrimaquineThe serum concentration of Irinotecan can be increased when it is combined with Primaquine.Approved
PrimidoneThe serum concentration of Irinotecan can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Procarbazine.Approved, Investigational
ProgesteroneThe serum concentration of Irinotecan can be increased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Irinotecan can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Irinotecan can be increased when it is combined with Propafenone.Approved
PropofolThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Propofol.Approved, Investigational, Vet Approved
PropylthiouracilThe risk or severity of adverse effects can be increased when Irinotecan is combined with Propylthiouracil.Approved, Investigational
ProtriptylineThe serum concentration of Irinotecan can be increased when it is combined with Protriptyline.Approved
QuercetinThe serum concentration of Irinotecan can be increased when it is combined with Quercetin.Experimental, Investigational
QuinacrineThe serum concentration of Irinotecan can be increased when it is combined with Quinacrine.Approved, Investigational
QuinidineThe serum concentration of Irinotecan can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Irinotecan can be decreased when it is combined with Quinine.Approved
RabeprazoleThe serum concentration of Irinotecan can be increased when it is combined with Rabeprazole.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Irinotecan.Approved, Investigational
RaltitrexedThe risk or severity of adverse effects can be increased when Irinotecan is combined with Raltitrexed.Approved, Investigational
RanitidineThe serum concentration of Irinotecan can be increased when it is combined with Ranitidine.Approved
ReboxetineThe serum concentration of Irinotecan can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Regorafenib.Approved
RepaglinideThe excretion of Repaglinide can be decreased when combined with Irinotecan.Approved, Investigational
ReserpineThe serum concentration of Irinotecan can be increased when it is combined with Reserpine.Approved, Investigational
Reversin 121The serum concentration of Irinotecan can be increased when it is combined with Reversin 121.Experimental
RifampicinThe serum concentration of Irinotecan can be decreased when it is combined with Rifampicin.Approved
RifamycinThe serum concentration of Irinotecan can be decreased when it is combined with Rifamycin.Investigational
RifapentineThe serum concentration of Irinotecan can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Irinotecan can be decreased when it is combined with Rifaximin.Approved, Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with Irinotecan.Approved, Investigational
RilpivirineThe serum concentration of Irinotecan can be increased when it is combined with Rilpivirine.Approved
RimexoloneThe serum concentration of Irinotecan can be decreased when it is combined with Rimexolone.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Irinotecan.Investigational
RisperidoneThe metabolism of Irinotecan can be decreased when combined with Risperidone.Approved, Investigational
RitonavirThe serum concentration of Irinotecan can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Irinotecan.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Irinotecan.Approved
RosuvastatinThe excretion of Rosuvastatin can be decreased when combined with Irinotecan.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Irinotecan.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Irinotecan.Approved, Investigational
RucaparibThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Rucaparib.Approved, Investigational
RuxolitinibThe risk or severity of adverse effects can be increased when Irinotecan is combined with Ruxolitinib.Approved
SafinamideThe serum concentration of Irinotecan can be increased when it is combined with Safinamide.Approved, Investigational
SalinomycinThe serum concentration of Irinotecan can be increased when it is combined with Salinomycin.Vet Approved
Salmonella typhi ty2 vi polysaccharide antigenThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Irinotecan.Approved
Salmonella typhi Ty21a live antigenThe risk or severity of infection can be increased when Salmonella typhi Ty21a live antigen is combined with Irinotecan.Approved
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Irinotecan.Approved
SaquinavirThe serum concentration of Irinotecan can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Irinotecan can be decreased when used in combination with Sarilumab.Approved, Investigational
SecukinumabThe risk or severity of adverse effects can be increased when Secukinumab is combined with Irinotecan.Approved
SelexipagThe excretion of Selexipag can be decreased when combined with Irinotecan.Approved
SertralineThe serum concentration of Irinotecan can be increased when it is combined with Sertraline.Approved
Silibinin AThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Silibinin A.Experimental, Investigational
SiltuximabThe serum concentration of Irinotecan can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Irinotecan can be increased when it is combined with Simeprevir.Approved
SimvastatinThe excretion of Simvastatin can be decreased when combined with Irinotecan.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Irinotecan.Approved, Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Irinotecan.Approved, Investigational
Sodium aurothiomalateThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Sodium aurothiomalate.Approved, Investigational
SorafenibThe serum concentration of Irinotecan can be increased when it is combined with Sorafenib.Approved, Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Irinotecan.Investigational
St. John's WortThe therapeutic efficacy of Irinotecan can be decreased when used in combination with St. John's Wort.Approved, Investigational, Nutraceutical
StaurosporineThe serum concentration of Irinotecan can be increased when it is combined with Staurosporine.Experimental
SteproninThe risk or severity of adverse effects can be increased when Irinotecan is combined with Stepronin.Approved
StiripentolThe serum concentration of Irinotecan can be increased when it is combined with Stiripentol.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Irinotecan.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Sulfasalazine.Approved
SunitinibThe risk or severity of adverse effects can be increased when Irinotecan is combined with Sunitinib.Approved, Investigational
SuvorexantThe serum concentration of Irinotecan can be increased when it is combined with Suvorexant.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Irinotecan.Approved, Investigational
TamoxifenThe serum concentration of Irinotecan can be increased when it is combined with Tamoxifen.Approved
TariquidarThe serum concentration of Irinotecan can be increased when it is combined with Tariquidar.Investigational
Taurocholic AcidThe serum concentration of Irinotecan can be increased when it is combined with Taurocholic Acid.Experimental
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Irinotecan.Investigational
Technetium Tc-99m mebrofeninThe excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Irinotecan.Approved
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Irinotecan is combined with Tedizolid phosphate.Approved
TelaprevirThe serum concentration of Irinotecan can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Irinotecan can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Irinotecan can be increased when it is combined with Telmisartan.Approved, Investigational
TemocaprilThe excretion of Temocapril can be decreased when combined with Irinotecan.Experimental, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Temozolomide.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Irinotecan is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Irinotecan.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Irinotecan is combined with Tepoxalin.Vet Approved
TerfenadineThe serum concentration of Irinotecan can be increased when it is combined with Terfenadine.Approved, Withdrawn
TeriflunomideThe serum concentration of Irinotecan can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Irinotecan can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Irinotecan can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Irinotecan can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Irinotecan can be increased when it is combined with Testosterone enanthate.Approved
Testosterone propionateThe serum concentration of Irinotecan can be decreased when it is combined with Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Irinotecan can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetrandrineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Tetrandrine.Experimental
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Irinotecan.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Irinotecan.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Irinotecan.Approved, Investigational
TicagrelorThe serum concentration of Irinotecan can be increased when it is combined with Ticagrelor.Approved
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Irinotecan.Approved
TipifarnibThe serum concentration of Irinotecan can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe serum concentration of Irinotecan can be increased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Irinotecan is combined with Tixocortol.Approved, Withdrawn
TocilizumabThe serum concentration of Irinotecan can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with Irinotecan.Approved, Investigational
TofacitinibIrinotecan may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolvaptanThe serum concentration of Irinotecan can be increased when it is combined with Tolvaptan.Approved
TopiroxostatThe serum concentration of Irinotecan can be increased when it is combined with Topiroxostat.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Topotecan.Approved, Investigational
ToremifeneThe serum concentration of Irinotecan can be increased when it is combined with Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with Irinotecan.Approved, Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Irinotecan is combined with Trabectedin.Approved, Investigational
TrastuzumabThe risk or severity of adverse effects can be increased when Irinotecan is combined with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Trastuzumab emtansine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Irinotecan.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Irinotecan.Approved, Vet Approved
TrifluoperazineThe serum concentration of Irinotecan can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Irinotecan can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrifluridineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Trifluridine.Approved, Investigational
TrilostaneThe risk or severity of adverse effects can be increased when Irinotecan is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe serum concentration of Irinotecan can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Triptolide.Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Irinotecan is combined with Trofosfamide.Investigational
TroleandomycinThe serum concentration of Irinotecan can be increased when it is combined with Troleandomycin.Approved
Typhoid VaccineThe therapeutic efficacy of Typhoid Vaccine can be decreased when used in combination with Irinotecan.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Irinotecan is combined with Ulobetasol.Approved
UstekinumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Irinotecan.Approved, Investigational
ValinomycinThe serum concentration of Irinotecan can be increased when it is combined with Valinomycin.Experimental
Valproic AcidThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Valproic Acid.Approved, Investigational
ValsartanThe excretion of Valsartan can be decreased when combined with Irinotecan.Approved, Investigational
ValspodarThe serum concentration of Irinotecan can be increased when it is combined with Valspodar.Investigational
VandetanibThe serum concentration of Irinotecan can be increased when it is combined with Vandetanib.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/Attenuated) is combined with Irinotecan.Approved
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Irinotecan.Approved
VedolizumabThe risk or severity of adverse effects can be increased when Vedolizumab is combined with Irinotecan.Approved
VelpatasvirThe serum concentration of Irinotecan can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe serum concentration of Irinotecan can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Irinotecan can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Irinotecan can be increased when it is combined with Verapamil.Approved
Vibrio cholerae CVD 103-HgR strain live antigenThe risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Irinotecan.Approved, Investigational
Vibrio cholerae CVD 103-HgR strain live antigenThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Irinotecan.Approved, Investigational
VilanterolThe risk or severity of adverse effects can be increased when Irinotecan is combined with Vilanterol.Approved
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Irinotecan.Approved
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Irinotecan.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Irinotecan.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Irinotecan.Approved, Investigational
VismodegibThe serum concentration of Irinotecan can be increased when it is combined with Vismodegib.Approved, Investigational
VoacamineThe serum concentration of Irinotecan can be increased when it is combined with Voacamine.Approved, Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Voclosporin is combined with Irinotecan.Investigational
VorapaxarThe serum concentration of Irinotecan can be increased when it is combined with Vorapaxar.Approved
VoriconazoleThe serum concentration of Irinotecan can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of adverse effects can be increased when Irinotecan is combined with Vorinostat.Approved, Investigational
VoxilaprevirThe serum concentration of Irinotecan can be increased when it is combined with Voxilaprevir.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Irinotecan is combined with Wortmannin.Experimental
Yellow Fever VaccineThe risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Irinotecan.Approved, Investigational
Yellow Fever VaccineThe therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Irinotecan.Approved, Investigational
YohimbineThe serum concentration of Irinotecan can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZidovudineThe risk or severity of adverse effects can be increased when Irinotecan is combined with Zidovudine.Approved
ZiprasidoneThe metabolism of Irinotecan can be decreased when combined with Ziprasidone.Approved
ZomepiracThe serum concentration of Irinotecan can be increased when it is combined with Zomepirac.Withdrawn
ZosuquidarThe serum concentration of Irinotecan can be increased when it is combined with Zosuquidar.Investigational
Food Interactions
Not Available

References

Synthesis Reference
US4604463
General References
  1. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15;22(8):1382-8. Epub 2004 Mar 8. [PubMed:15007088]
  2. O'Dwyer PJ, Catalano RB: Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol. 2006 Oct 1;24(28):4534-8. [PubMed:17008691]
  3. Ramesh M, Ahlawat P, Srinivas NR: Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23. doi: 10.1002/bmc.1345. [PubMed:19852077]
  4. Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997 Oct;33(4):245-59. [PubMed:9342501]
External Links
Human Metabolome Database
HMDB0014900
KEGG Drug
D08086
KEGG Compound
C16641
PubChem Compound
60838
PubChem Substance
46505871
ChemSpider
54825
BindingDB
50128267
ChEBI
80630
ChEMBL
CHEMBL481
Therapeutic Targets Database
DAP001339
PharmGKB
PA450085
HET
CP0
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Irinotecan
ATC Codes
L01XX19 — Irinotecan
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
1u65
FDA label
Download (132 KB)
MSDS
Download (36.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Sarcomas1
0CompletedTreatmentDiffuse Intrinsic Pontine Glioma (DIPG) / Newly Diagnosed High-Grade Gliomas1
0Not Yet RecruitingTreatmentChildhood CNS Tumor1
0RecruitingTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Unresectable Pancreatic Carcinoma1
0RecruitingTreatmentNeuroblastoma (NB)1
0TerminatedTreatmentGlioblastomas / Gliosarcoma / Neoplasms, Brain1
1Active Not RecruitingBasic ScienceAdvanced Colorectal Cancer1
1Active Not RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Adenocarcinoma of the Gallbladder / Adenocarcinoma of Unknown Primary / Adult Primary Cholangiocellular Carcinoma / Advanced Adult Primary Liver Cancer / Advanced Gastric Cancer / Cholangiocarcinoma of the Extrahepatic Bile Duct / Cholangiocarcinoma of the Gallbladder / Diffuse Adenocarcinoma of the Stomach / Duct Cell Adenocarcinoma of the Pancreas / Intestinal Adenocarcinoma of the Stomach / Localized Unresectable Adult Primary Liver Cancer / Metastatic Carcinoma of Unknown Primary / Metastatic Extrahepatic Bile Duct Cancer / Mixed Adenocarcinoma of the Stomach / Mucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Newly Diagnosed Carcinoma of Unknown Primary / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage III Pancreatic Cancer / Stage IIIA Colon Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Gastric Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Gallbladder Cancer / Stage IIIB Gastric Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Gastric Cancer / Stage IIIC Rectal Cancer / Stage IV Pancreatic Cancer / Stage IVA Colon Cancer / Stage IVA Gallbladder Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Gallbladder Cancer / Stage IVB Rectal Cancer / Unresectable Extrahepatic Bile Duct Cancer1
1Active Not RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer1
1Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas1
1Active Not RecruitingTreatmentAdult Hodgkin Lymphoma / Adult Non-Hodgkin's Lymphoma / Advanced Malignant Solid Neoplasm / Carcinoma, Breast / Carcinoma, Pancreatic / Colon Carcinoma / Deleterious BRCA1 Gene Mutation / Estrogen Receptor Negative / HER2/Neu Negative / Lung, Carcinoma / Lymphoma, Hodgkins / Metastatic Colon Cancer / Metastatic Malignant Neoplasm / Metastatic Malignant Solid Neoplasm / Metastatic Solid Neoplasm / Neoplasms, Advanced Solid / Non-Hodgkin's Lymphoma (NHL) / Ovarian Carcinoma / Progesterone Receptor Negative / Solid Neoplasms / Stage III Breast Cancer / Stage III Breast Cancer AJCC V7 / Stage III Colon Cancer / Stage III Colon Cancer AJCC v7 / Stage III Lung Cancer / Stage III Lung Cancer AJCC v7 / Stage III Ovarian Cancer / Stage III Ovarian Cancer AJCC v6 and v7 / Stage III Pancreatic Cancer / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage IIIA Breast Cancer / Stage IIIA Breast Cancer AJCC v7 / Stage IIIA Colon Cancer / Stage IIIA Colon Cancer AJCC v7 / Stage IIIA Ovarian Cancer / Stage IIIA Ovarian Cancer AJCC v6 and v7 / Stage IIIB Breast Cancer / Stage IIIB Breast Cancer AJCC v7 / Stage IIIB Colon Cancer / Stage IIIB Colon Cancer AJCC v7 / Stage IIIB Ovarian Cancer / Stage IIIB Ovarian Cancer AJCC v6 and v7 / Stage IIIC Breast Cancer / Stage IIIC Breast Cancer AJCC v7 / Stage IIIC Colon Cancer / Stage IIIC Colon Cancer AJCC v7 / Stage IIIC Ovarian Cancer / Stage IIIC Ovarian Cancer AJCC v6 and v7 / Stage IV Breast Cancer / Stage IV Breast Cancer AJCC v6 and v7 / Stage IV Colon Cancer AJCC v7 / Stage IV Lung Cancer / Stage IV Lung Cancer AJCC v7 / Stage IV Ovarian Cancer / Stage IV Ovarian Cancer AJCC v6 and v7 / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v7 / Stage IVA Colon Cancer / Stage IVA Colon Cancer AJCC v7 / Stage IVA Pancreatic Cancer / Stage IVB Colon Cancer / Stage IVB Colon Cancer AJCC v7 / Stage IVB Pancreatic Cancer / Triple-Negative Breast Carcinoma / Unresectable Malignant Neoplasm / Unresectable Solid Neoplasm1
1Active Not RecruitingTreatmentAdult Solid Neoplasm1
1Active Not RecruitingTreatmentAdvanced Solid Tumors1
1Active Not RecruitingTreatmentCancer, Breast / Colorectal Cancers / Esophagogastric Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Tumors1
1Active Not RecruitingTreatmentKRAS Mutant Metastatic Colorectal Cancer1
1Active Not RecruitingTreatmentMalignant Neoplasm of Colon / Rectal Carcinoma1
1Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas2
1Active Not RecruitingTreatmentMetastatic Cancers / Unspecified Adult Solid Tumor1
1Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
1Active Not RecruitingTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IIIA Colon Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1Active Not RecruitingTreatmentNeuroblastomas1
1Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
1Active Not RecruitingTreatmentTumors, Solid1
1CompletedDiagnosticCancers / Refractory Solid Tumors1
1CompletedDiagnosticMalignant Lymphomas / Tumors1
1CompletedTreatmentAIDS-related Peripheral/Systemic Lymphoma / AIDS-related Primary CNS Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Hodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentAdenocarcinomas / Colorectal / Metastatic1
1CompletedTreatmentAdenocarcinomas / Malignant Neoplasm of Pancreas / Neoplasms, Pancreatic1
1CompletedTreatmentAdenocarcinomas / Malignant Neoplasm of Stomach1
1CompletedTreatmentAdvanced Adult Primary Liver Cancer / Advanced Gastric Cancer / Carcinoma of the Appendix / Estrogen Receptor-negative Breast Cancer / Extensive Stage Small Cell Lung Cancer / Gastrointestinal Stromal Tumors / HER2-Negative Breast Cancer / Metastatic Colon Cancer / Metastatic Gastrointestinal Carcinoid Tumor / Non-Small Cell Lung Cancer Recurrent / Ovarian Sarcoma / Ovarian Stromal Cancer / Progesterone Receptor-negative Breast Cancer / Recurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Adult Primary Liver Cancer / Recurrent Anal Cancer / Recurrent Basal Cell Carcinoma of the Lip / Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor / Recurrent Breast Cancer / Recurrent Cervical Cancer / Recurrent Colon Cancer / Recurrent Endometrial Carcinoma / Recurrent Esophageal Cancer / Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Recurrent Extrahepatic Bile Duct Cancer / Recurrent Gallbladder Cancer / Recurrent Gastric Cancer / Recurrent Gastrointestinal Carcinoid Tumor / Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Recurrent Lymphoepithelioma of the Nasopharynx / Recurrent Lymphoepithelioma of the Oropharynx / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Recurrent Mucoepidermoid Carcinoma of the Oral Cavity / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Pancreatic Cancer / Recurrent Prostate Cancer / Recurrent Rectal Cancer / Recurrent Salivary Gland Cancer / Recurrent Small Intestine Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Refractory Small cell lung cancer / Small Intestine Adenocarcinoma / Small Intestine Leiomyosarcoma / Small Intestine Lymphoma / Stage IV Adenoid Cystic Carcinoma of the Oral Cavity / Stage IV Anal Cancer / Stage IV Basal Cell Carcinoma of the Lip / Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor / Stage IV Breast Cancer / Stage IV Endometrial Carcinoma / Stage IV Esophageal Cancer / Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Lymphoepithelioma of the Oropharynx / Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Stage IV Mucoepidermoid Carcinoma of the Oral Cavity / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Stage IV Pancreatic Cancer / Stage IV Prostate Cancer / Stage IV Rectal Cancer / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Verrucous Carcinoma of the Oral Cavity / Stage IVA Cervical Cancer / Stage IVB Cervical Cancer / Triple-Negative Breast Cancer (TNBC) / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer / Unspecified Adult Solid Tumor, Protocol Specific / Untreated Metastatic Squamous Neck Cancer With Occult Primary1
1CompletedTreatmentAdvanced Gastrointestinal Tumors1
1CompletedTreatmentAdvanced Nonhematologic Malignancies1
1CompletedTreatmentAdvanced Solid Malignancies2
1CompletedTreatmentAdvanced Solid Tumors2
1CompletedTreatmentAdvanced Solid Tumors / Colorectal Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Head and Neck Cancer / Triple Negative Breast Cancer (TNBC)1
1CompletedTreatmentAdvanced Solid Tumors / Hepatocellular,Carcinoma1
1CompletedTreatmentAnal Carcinoma / Carcinoid tumour of the gastrointestinal tract / Carcinoma of the Appendix / Colorectal Cancers / Esophageal Cancers / Extrahepatic Bile Duct Cancer / Gallbladder Cancer / Gastrointestinal Stromal Tumors / Liver Cancer / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Small Intestine Cancer1
1CompletedTreatmentAnal Carcinoma / Carcinoid tumour of the gastrointestinal tract / Colorectal Cancers / Esophageal Cancers / Extrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Small Intestine Cancer1
1CompletedTreatmentAstrocytoma, Oligoastrocytoma, Mixed / Ganglioglioma / Ganglioneuroma / Glioblastoma Multiforme Glioma / Gliomas1
1CompletedTreatmentBile Duct Carcinoma / Duodenum Cancer / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach1
1CompletedTreatmentBladder Cancers / Cancer, Breast / Colorectal Cancers / Lung Cancers / Malignant Neoplasm of Pancreas / Renal Cancers1
1CompletedTreatmentBrain and Central Nervous System Tumors4
1CompletedTreatmentBrain and Central Nervous System Tumors / Neuroblastomas1
1CompletedTreatmentBrain and Central Nervous System Tumors / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentBrain and Nervous System / Cancers1
1CompletedTreatmentCancer, Advanced1
1CompletedTreatmentCancer, Advanced / Liver Cancer1
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentCancers2
1CompletedTreatmentCancers / Tumors, Solid1
1CompletedTreatmentCarcinoma, Colorectal1
1CompletedTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1CompletedTreatmentCervix Cancer1
1CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Central Nervous System Germ Cell Tumor / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Liver Cancer / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway Glioma / Recurrent Colon Cancer / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Melanoma / Recurrent Nasopharyngeal Cancer / Recurrent Neuroblastoma / Recurrent Osteosarcoma / Recurrent Wilms Tumor and Other Childhood Kidney Tumors / Recurrent/Refractory Childhood Hodgkin Lymphoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentColorectal Cancers8
1CompletedTreatmentColorectal Cancers / Diarrhea1
1CompletedTreatmentColorectal Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Other Tumors With EGFR Dependence / Squamous Cell Head and Neck Cancer / Triple Negative Breast Cancer (TNBC)1
1CompletedTreatmentColorectal Cancers / Neoplasms, Colorectal1
1CompletedTreatmentDiarrhea / Drug/Agent Toxicity by Tissue/Organ / Neuroblastomas1
1CompletedTreatmentDiarrhea / Neoplasms1
1CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Malignant Lymphomas / Neutropenias / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentEsophageal Cancers1
1CompletedTreatmentEsophageal Cancers / Liver Cancer / Malignant Neoplasm of Stomach1
1CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
1CompletedTreatmentEwing's Sarcoma Family of Tumors / Neoplasms, Brain / Neuroblastomas / Rhabdomyosarcoma and Other Soft Tissue Sarcomas / Sarcoma, Osteogenic1
1CompletedTreatmentGastro-Intestinal Cancer1
1CompletedTreatmentGlioblastomas2
1CompletedTreatmentGlioblastomas / Gliosarcoma1
1CompletedTreatmentLeukemias1
1CompletedTreatmentCancer treatment / Liver Dysfunction / Neoplasms, Solid Tumor / Unspecified Adult Solid Tumor1
1CompletedTreatmentLung Cancers7
1CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentMetastatic Colon Cancer / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer / Stage IV Rectal Cancer1
1CompletedTreatmentMetastatic Colon Cancer / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Rectal Cancer1
1CompletedTreatmentMetastatic Colorectal Cancers3
1CompletedTreatmentNeoplasms1
1CompletedTreatmentNeoplasms Malignant1
1CompletedTreatmentNeoplasms, Gastrointestinal1
1CompletedTreatmentNeoplasms, Pancreatic2
1CompletedTreatmentNeuroblastomas2
1CompletedTreatmentRecurrent Colon Carcinoma / Recurrent Rectal Carcinoma / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1CompletedTreatmentRefractory Solid Tumors in Children1
1CompletedTreatmentSquamous Cell Carcinoma of Esophagus1
1CompletedTreatmentStomach Neoplasms1
1CompletedTreatmentTumors1
1CompletedTreatmentTumors, Central Nervous System1
1CompletedTreatmentTumors, Solid3
1CompletedTreatmentUnresectable Advanced Cancer1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific29
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific6
1Enrolling by InvitationOtherMetastatic Colorectal Cancers1
1Enrolling by InvitationTreatmentHigh Grade Glioma (HGG)1
1Not Yet RecruitingTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1Not Yet RecruitingTreatmentMetastatic Colorectal Cancers1
1Not Yet RecruitingTreatmentTumors, Solid1
1RecruitingOtherPediatric Oncology1
1RecruitingTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligoastrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Gliomas / Recurrent Adult Brain Tumor1
1RecruitingTreatmentAdult Solid Neoplasm / Advanced Malignant Solid Neoplasm / Metastatic Malignant Neoplasm / Metastatic Malignant Solid Neoplasm / Metastatic Solid Neoplasm / Neoplasms, Advanced Solid / Refractory Malignant Neoplasm / Unresectable Malignant Neoplasm / Unresectable Solid Neoplasm1
1RecruitingTreatmentAdvanced Cancers2
1RecruitingTreatmentAdvanced Solid Tumors1
1RecruitingTreatmentAdvanced Solid Tumours1
1RecruitingTreatmentCancer, Advanced / Malignant Solid Tumours / Metastatic Cancers1
1RecruitingTreatmentChildhood Solid Neoplasm / Recurrent Central Nervous System Neoplasm / Recurrent Malignant Solid Neoplasm / Recurrent Solid Neoplasm / Refractory Central Nervous System Neoplasm / Refractory Malignant Solid Neoplasm1
1RecruitingTreatmentChildhood Solid Tumors1
1RecruitingTreatmentColorectal Cancers / Malignant Neoplasms of Digestive Organs1
1RecruitingTreatmentDigestive Cancers1
1RecruitingTreatmentEwing's Sarcoma (ES)2
1RecruitingTreatmentGastrooesophageal Cancer1
1RecruitingTreatmentMalignant Neoplasm of Pancreas1
1RecruitingTreatmentMetastatic Colorectal Cancers3
1RecruitingTreatmentNeoplasms Metastasis1
1RecruitingTreatmentPrimary Brain Tumors / Tumors, Solid1
1RecruitingTreatmentRecurrent Central Nervous System Neoplasm / Recurrent Lymphoma / Recurrent Malignant Solid Neoplasm / Refractory Central Nervous System Neoplasm / Refractory Lymphomas / Refractory Malignant Solid Neoplasm1
1RecruitingTreatmentRefractory Solid Tumors / Relapsed Solid Tumors1
1RecruitingTreatmentSarcomas1
1RecruitingTreatmentSolid Tumor, Unspecified, Adult1
1RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
1RecruitingTreatmentTumors, Solid2
1SuspendedTreatmentAdvanced Gastric Cancer / Estrogen Receptor Negative / HER2/Neu Negative / Malignant Solid Neoplasm / Neuroendocrine Neoplasms / Progesterone Receptor Negative / Recurrent, IV-B Cervical cancer / Stage IIB Cervical Cancer / Stage IIIA Cervical Cancer / Stage IIIB Cervical Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Gastric Cancer AJCC v7 / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Cancer / Stage IV Small Cell Lung Carcinoma / Triple-Negative Breast Carcinoma1
1TerminatedBasic ScienceCancer, Advanced1
1TerminatedTreatmentAdvanced Solid Malignancies / Advanced Solid Tumors / Cancers1
1TerminatedTreatmentBone Cancer / Kidney Tumors / Neoplasms / Neuroblastomas / Tumors, Solid1
1TerminatedTreatmentColorectal Cancers1
1TerminatedTreatmentColorectal Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentEsophageal Cancers1
1TerminatedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach2
1TerminatedTreatmentMalignant Gliomas1
1TerminatedTreatmentMalignant Neoplasm of Pancreas1
1TerminatedTreatmentMelanoma / Neoplasm Metastases / Neoplasms, Colorectal1
1TerminatedTreatmentNeoplasms1
1TerminatedTreatmentTumors, Solid1
1Unknown StatusTreatmentCancers1
1Unknown StatusTreatmentColorectal Cancers1
1Unknown StatusTreatmentLeukemia, Acute1
1Unknown StatusTreatmentNeoplasm, Gastric / Neoplasms, Colorectal / Secondary1
1Unknown StatusTreatmentRectal Carcinoma1
1Unknown StatusTreatmentTumors, Solid1
1Unknown StatusTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnBasic ScienceAdvanced Adenocarcinoma of the Colon or Rectum1
1WithdrawnTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
1WithdrawnTreatmentStage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
1, 2Active Not RecruitingTreatmentAdvanced Gastrointestinal Cancers1
1, 2Active Not RecruitingTreatmentNeuroblastomas1
1, 2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic2
1, 2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
1, 2CompletedTreatmentAdenocarcinoma of the Pancreas / Adenocarcinoma of Unknown Primary / Adult Cholangiocarcinoma / Advanced Gastric Cancer / Carcinoma of Gallbladder / Gastric Adenocarcinoma / Malignant Gastrointestinal Neoplasm / Pancreatic Adenocarcinoma Metastatic / Stage III Ampulla of Vater Cancer / Stage III Pancreatic Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Gastric Cancer / Stage IIIB Gallbladder Cancer / Stage IIIB Gastric Cancer / Stage IV Ampulla of Vater Cancer / Stage IV Gallbladder Cancer / Stage IV Pancreatic Cancer1
1, 2CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Metastatic Colon Cancer / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer / Stage IV Rectal Cancer2
1, 2CompletedTreatmentAdvanced Gastric Cancer1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors3
1, 2CompletedTreatmentBrain and Central Nervous System Tumors / Cognitive/Functional Effects / Long-Term Effects Secondary to Cancer Therapy in Adults / Long-Term Effects Secondary to Cancer Therapy in Children / Poor Performance Status / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentCarcinoma, Colorectal / CRC1
1, 2CompletedTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1, 2CompletedTreatmentCarcinoma, Colorectal / Colorectal Tumors / Neoplasms, Colorectal1
1, 2CompletedTreatmentChemonaive / Extensive Stage Lung Cancer / Lung Cancer Small Cell Lung Cancer (SCLC)1
1, 2CompletedTreatmentColorectal Cancers8
1, 2CompletedTreatmentLung Cancers1
1, 2CompletedTreatmentMalignant Gliomas1
1, 2CompletedTreatmentMalignant Neoplasm of Stomach1
1, 2CompletedTreatmentMetastatic Colorectal Cancer (MCRC)1
1, 2CompletedTreatmentMetastatic Colorectal Cancers3
1, 2CompletedTreatmentPediatric Solid Tumors1
1, 2CompletedTreatmentRectal Carcinoma1
1, 2CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2Not Yet RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Biliary System Disorder / BRCA1 Gene Mutation / Brca2 Gene Mutation / Homologous Recombination Deficiency / PALB2 Gene Mutation / Pancreatic Adenocarcinoma Metastatic / Stage IV Colorectal Cancer AJCC v7 / Stage IV Pancreatic Cancer AJCC v6 and v7 / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer AJCC v71
1, 2Not Yet RecruitingTreatmentCancer of Colon / Cancer of Liver / Cancer of Pancreas / Cancer of Rectum / Cancer, Gall Bladder / Glioblastoma Multiforme (GBM) / Myeloma Multiple1
1, 2Not Yet RecruitingTreatmentMetastatic Colorectal Cancers / Tumors, Solid1
1, 2RecruitingTreatmentAdenocarcinomas / Digestive System Diseases / Digestive System Neoplasms / Endocrine Gland Neoplasms / Endocrine System Diseases / Neoplasm, Glandular / Neoplasms / Neoplasms Pancreatic / Neoplasms, Pancreatic / Pancreatic Diseases1
1, 2RecruitingTreatmentAdvanced Gastric Cancer / Colorectal Adenocarcinoma / Gastric Adenocarcinoma / Non-Resectable Cholangiocarcinoma / Pancreatic Adenocarcinoma Metastatic / Stage IV Colorectal Cancer / Stage IV Pancreatic Cancer / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer / Unresectable Pancreatic Carcinoma1
1, 2RecruitingTreatmentAnaplastic Astrocytoma (AA) / Brain Stem Gliomas / Diffuse Intrinsic Pontine Glioma (DIPG) / DIPG / Glioblastoma Multiforme (GBM) / Glioma, Astrocytic / Gliosarcoma / Low-Grade Gliomas / Optic Nerve Glioma / Pilocytic Astrocytoma / Pilomyxoid Astrocytoma / Pleomorphic Xanthoastrocytoma1
1, 2RecruitingTreatmentCentral Nervous System Embryonal Tumor With Rhabdoid Features / Central Nervous System Embryonal Tumor, Not Otherwise Specified / Central Nervous System Ganglioneuroblastoma / Childhood Central Nervous System Neoplasm / Childhood Solid Neoplasm / Embryonal Tumor With Multilayered Rosettes, C19MC-Altered / Pinealoblastoma / Primary Central Nervous System Neoplasm / Recurrent Childhood Central Nervous System Embryonal Neoplasm / Recurrent Childhood Medulloblastoma / Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Malignant Solid Neoplasm / Recurrent Medulloblastoma / Recurrent Neuroblastoma / Recurrent Rhabdomyosarcoma / Recurrent Solid Neoplasm / Refractory Malignant Solid Neoplasm / Refractory Medulloblastoma / Refractory Neuroblastoma / Refractory Rhabdomyosarcoma1
1, 2RecruitingTreatmentChildren, Adolescents and Young Adults With Refractory or Recurrent Malignancies1
1, 2RecruitingTreatmentColorectal Cancers / Malignant Neoplasm of Pancreas1
1, 2RecruitingTreatmentColorectal Cancers / Metastatic Colorectal Cancers / RAS Wild Type Colorectal Cancer / Refractory Colorectal Cancer1
1, 2RecruitingTreatmentEwing's Sarcoma (ES) / Non-rhabdomyosarcoma Soft Tissue Sarcomas / Refractory or Recurrent Solid Tumors / Rhabdomyosarcomas1
1, 2RecruitingTreatmentHigh-Grade Gliomas1
1, 2RecruitingTreatmentIrinotecan Sensitive Cancers / Non Small Cell Lung Carcinoma (NSCLC) / Small Cell Lung Carcinoma1
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas1
1, 2RecruitingTreatmentNeoplasms, Colorectal1
1, 2TerminatedTreatmentCancer, Advanced / Cancer, Breast / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Neoplasm of Pancreas / Ovarian / Sarcomas1
1, 2TerminatedTreatmentCancer, Advanced / Carcinoma, Colorectal / Endometrial / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Renal Cell Adenocarcinoma / Uterine1
1, 2TerminatedTreatmentCarcinoma, Colorectal1
1, 2TerminatedTreatmentColorectal Cancers1
1, 2TerminatedTreatmentExtensive Stage Unresectable / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2TerminatedTreatmentMalignant Neoplasm of Pancreas1
1, 2TerminatedTreatmentMetastatic Cancers1
1, 2TerminatedTreatmentMetastatic Colorectal Cancers1
1, 2TerminatedTreatmentNeoplasms1
1, 2TerminatedTreatmentNeuroblastomas1
1, 2TerminatedTreatmentUnresectable Metastatic Colo-rectal Cancer1
1, 2Unknown StatusTreatmentAdvanced Non-Small Cell Lung Cancer1
1, 2WithdrawnTreatmentAdenocarcinoma of the Pancreas / Colon Adenocarcinoma / Pancreatic Adenocarcinoma Metastatic / Pancreatic Ductal Adenocarcinoma / Rectal Adenocarcinoma / Stage III Pancreatic Cancer / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IV Pancreatic Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1, 2WithdrawnTreatmentColorectal Cancers1
1, 2WithdrawnTreatmentGlioblastoma Multiforme (GBM)1
1, 2WithdrawnTreatmentMalignant Neoplasm of Pancreas1
1, 2WithdrawnTreatmentMalignant Neoplasm of Stomach1
2Active Not RecruitingOtherPancreatic Adenocarcinoma Metastatic1
2Active Not RecruitingTreatmentAdenocarcinoma of Ampulla / Ductal Adenocarcinoma of Pancreas1
2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas2
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers / Malignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma / Malignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentBiliary Cancer / Cholangiocarcinomas1
2Active Not RecruitingTreatmentBiliary Tract Neoplasms1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentColorectal Adenocarcinoma / KRAS wt Allele / Metastatic Colorectal Cancers / NRAS wt Allele / RAS Wild Type / Stage IV Colorectal Cancer / Stage IV Colorectal Cancer AJCC v7 / Stage IVA Colorectal Cancer / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer / Stage IVB Colorectal Cancer AJCC v71
2Active Not RecruitingTreatmentColorectal Cancer Liver Metastases1
2Active Not RecruitingTreatmentColorectal Cancers6
2Active Not RecruitingTreatmentColorectal Cancers / Metastatic Cancers1
2Active Not RecruitingTreatmentEsophageal Cancers2
2Active Not RecruitingTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentEwing's Sarcoma (ES)1
2Active Not RecruitingTreatmentGanglioneuroblastoma / Recurrent Neuroblastoma1
2Active Not RecruitingTreatmentGastric Adenocarcinoma / Neoplasms, Gastrointestinal1
2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas2
2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach / Unresectable1
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentMetastatic Colorectal Cancers6
2Active Not RecruitingTreatmentMetastatic Colorectal Cancers / Recurrent Colorectal Cancer1
2Active Not RecruitingTreatmentNeoplasms, Colorectal1
2Active Not RecruitingTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
2Active Not RecruitingTreatmentNeuroblastomas1
2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic / Recurrent Pancreatic Carcinoma / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v71
2Active Not RecruitingTreatmentPancreatic Cancer Metastatic1
2Active Not RecruitingTreatmentRectal Carcinoma2
2Active Not RecruitingTreatmentRecurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor1
2Active Not RecruitingTreatmentRecurrent Colorectal Carcinoma / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
2Active Not RecruitingTreatmentRecurrent Small Intestine Cancer / Small Intestine Adenocarcinoma1
2Active Not RecruitingTreatmentRhabdomyosarcomas1
2Active Not RecruitingTreatmentSarcomas1
2Active Not RecruitingTreatmentMCRC1
2CompletedNot AvailableMalignant Gliomas1
2CompletedDiagnosticUpper Gastrointestinal Tumours1
2CompletedSupportive CareColorectal Cancers1
2CompletedSupportive CareColorectal Cancers / Nausea and Vomiting1
2CompletedTreatmentAdenocarcinoma Of Esophagus / Squamous Cell Carcinoma of Esophagus1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of the Pancreas1
2CompletedTreatmentAdenocarcinoma of the Stomach / Advanced Gastric Cancer / Malignant Neoplasm of Stomach Stage II / Stage III Gastric Cancer1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Advanced Gastric Cancer / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Gastric Cancer / Stage IIIA Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer3
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Advanced Gastric Cancer / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer1
2CompletedTreatmentAdult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Embryonal Rhabdomyosarcoma / Metastatic Childhood Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
2CompletedTreatmentAdvanced Colorectal Cancer1
2CompletedTreatmentAdvanced Gastric Cancer / Gastro-esophageal Junction Cancer1
2CompletedTreatmentAlveolar Childhood Rhabdomyosarcoma / Embryonal Childhood Rhabdomyosarcoma / Embryonal-botryoid Childhood Rhabdomyosarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Rhabdomyosarcoma1
2CompletedTreatmentAstrocytomas / Glioblastomas1
2CompletedTreatmentBiliary Tract Cancer1
2CompletedTreatmentBiliary Tract Neoplasms1
2CompletedTreatmentBladder Cancers1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2CompletedTreatmentBrain and Central Nervous System Tumors7
2CompletedTreatmentCancer of Esophagus / Cancer of the Esophagus / Esophageal Cancers / Esophagus Cancer / Neoplasms, Esophageal1
2CompletedTreatmentCancer of Stomach / Esophageal Cancers / Esophagus Cancer / Malignant Neoplasm of Stomach1
2CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Carcinoma1
2CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentCancer, Breast6
2CompletedTreatmentCancer, Breast / Metastatic Cancers1
2CompletedTreatmentCancers / Colorectal Cancers / Malignant Neoplasm of Colon / Metastatic Cancers / Metastatic Colorectal Cancers / Rectal Carcinoma1
2CompletedTreatmentCarcinoid tumour of the gastrointestinal tract / Islet Cell Tumor / Neoplastic Syndrome1
2CompletedTreatmentCarcinoma of Unknown Primary1
2CompletedTreatmentCarcinoma of Unknown Primary / Colorectal Cancers / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentCarcinoma of Unknown Primary / Neuroendocrine Carcinoma of the Skin / Neuroendocrine Carcinomas1
2CompletedTreatmentCarcinoma, Colorectal1
2CompletedTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors1
2CompletedTreatmentChildhood Central Nervous System Germ Cell Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood Infratentorial Ependymoma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Recurrent Childhood Visual Pathway Glioma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Neuroblastoma / Recurrent Osteosarcoma / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentChildhood Cerebral Anaplastic Astrocytoma / Childhood Oligodendroglioma / Childhood Spinal Cord Neoplasm / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma1
2CompletedTreatmentChildhood Renal Cell Carcinoma / Clear Cell Renal Cell Carcinoma / Clear Cell Sarcoma of the Kidney / Papillary Renal Cell Carcinoma / Rhabdoid Tumors of the Kidney (RTK) / Stage I Renal Cell Cancer / Stage I Renal Wilms Tumor / Stage II Renal Cell Cancer / Stage II Renal Wilms Tumor / Stage III Renal Cell Cancer / Stage III Renal Wilms Tumor / Stage IV Renal Cell Cancer / Stage IV Renal Wilms Tumor1
2CompletedTreatmentColorectal Cancer (CRC)1
2CompletedTreatmentColorectal Cancers39
2CompletedTreatmentColorectal Cancers / Hepatic Metastases1
2CompletedTreatmentColorectal Cancers / Malignant Neoplasm of Colon / Metastatic Colorectal Cancers / Skin Rash / Skin Toxicities1
2CompletedTreatmentColorectal Cancers / Metastatic Cancers4
2CompletedTreatmentColorectal Cancers / Neoplasms, Colorectal2
2CompletedTreatmentColorectal, Cancer1
2CompletedTreatmentEsophageal Cancers5
2CompletedTreatmentEsophageal Cancers / GE Junction Cancer / Malignant Neoplasm of Stomach1
2CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach11
2CompletedTreatmentEstrogen Receptor Negative (ER-Negative) Breast Cancer / Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer / Metastatic Brain Tumors / Progesterone Receptor Negative (PR-Negative) Breast Cancer1
2CompletedTreatmentExtensive Stage Small Cell Lung Cancer2
2CompletedTreatmentExtensive-Stage Small Cell Lung Cancer1
2CompletedTreatmentGallbladder Cancer1
2CompletedTreatmentGastrointestinal Cancers / Neuroendocrine Carcinomas1
2CompletedTreatmentGlioblastoma Multiforme (GBM)2
2CompletedTreatmentGlioblastoma Multiforme (GBM) / Gliomas1
2CompletedTreatmentGlioblastoma Multiforme (GBM) / Gliosarcoma1
2CompletedTreatmentGlioblastomas2
2CompletedTreatmentGlioblastomas / Gliosarcoma / Neoplasms, Brain1
2CompletedTreatmentGliomas / Medulloblastomas1
2CompletedTreatmentGliomas / Neoplasms, Brain1
2CompletedTreatmentHead and Neck Carcinoma3
2CompletedTreatmentLeukemias / Malignant Lymphomas1
2CompletedTreatmentLiver Cancer1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)5
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
2CompletedTreatmentLung Cancers16
2CompletedTreatmentLung Cancers / Small Cell Lung Carcinoma1
2CompletedTreatmentMalignant Gliomas1
2CompletedTreatmentMalignant Lymphomas1
2CompletedTreatmentMalignant Neoplasm of Colon / Rectum Cancer1
2CompletedTreatmentMalignant Neoplasm of Pancreas6
2CompletedTreatmentMalignant Neoplasm of Pancreas / Neoplasms, Pancreatic1
2CompletedTreatmentMalignant Neoplasm of Stomach7
2CompletedTreatmentMalignant Neoplasm of Stomach / Neoplasms, Esophageal1
2CompletedTreatmentMalignant Neoplasm of Stomach / Peritoneal Carcinomatosis1
2CompletedTreatmentMetastatic Colorectal Cancers15
2CompletedTreatmentNaive Unresectable Glioblastoma1
2CompletedTreatmentNeoplasms1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNeoplasms, Colorectal3
2CompletedTreatmentNeoplasms, Esophageal1
2CompletedTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
2CompletedTreatmentNeuroblastomas1
2CompletedTreatmentOesophageal Carcinoma1
2CompletedTreatmentPediatric High Risk Gliomas1
2CompletedTreatmentPenile Cancer1
2CompletedTreatmentRectal Carcinoma1
2CompletedTreatmentRectal Neoplasms1
2CompletedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2CompletedTreatmentRecurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Verrucous Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer1
2CompletedTreatmentRenal Cancers1
2CompletedTreatmentSarcomas3
2CompletedTreatmentSmall Cell Lung Carcinoma1
2CompletedTreatmentStomach Neoplasms2
2CompletedTreatmentTumors, Solid1
2CompletedTreatmentUterine Cervical Neoplasms1
2Enrolling by InvitationTreatmentLocally Advanced or Metastatic Pancreatic Cancer1
2Enrolling by InvitationTreatmentRectal Carcinoma1
2Not Yet RecruitingTreatmentAdvanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction1
2Not Yet RecruitingTreatmentBiliary Tract Cancer1
2Not Yet RecruitingTreatmentCarcinoma, Colorectal / Colorectal Adenocarcinoma / Colorectal Cancer With Hepatic Metastases / Colorectal Cancers / Hepatic Metastases1
2Not Yet RecruitingTreatmentCholangiocarcinomas1
2Not Yet RecruitingTreatmentColorectal Cancers1
2Not Yet RecruitingTreatmentColorectal Neoplasms, Malignant1
2Not Yet RecruitingTreatmentEfficacy and Safety1
2Not Yet RecruitingTreatmentMetastatic Biliary Tract Cancer1
2Not Yet RecruitingTreatmentMetastatic Colorectal Cancers3
2Not Yet RecruitingTreatmentPancreatic Ductal Adenocarcinoma1
2Not Yet RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
2RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Stage I Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Resectable Pancreatic Cancers / Resectable Pancreatic Carcinoma1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
2RecruitingTreatmentAdenocarcinomas / Neoplasms, Colorectal1
2RecruitingTreatmentAdvanced Colorectal Cancer1
2RecruitingTreatmentAdvanced Esophageal Carcinoma1
2RecruitingTreatmentAdvanced Pancreatic Cancer1
2RecruitingTreatmentBiliary Cancer1
2RecruitingTreatmentBreast Cancer Metastatic1
2RecruitingTreatmentCancer - Metastatic Colorectal / Cancers1
2RecruitingTreatmentCarcinoma, Colorectal / Metastatic Colorectal Cancers / Neoplasms Metastasis / Neoplasms, Colorectal1
2RecruitingTreatmentColo-rectal Cancer / Hepatic Metastases2
2RecruitingTreatmentColon Adenocarcinoma / ERBB2 Gene Amplification / Rectal Adenocarcinoma / Recurrent Colon Carcinoma / Recurrent Rectal Carcinoma / Stage III Colon Cancer AJCC v7 / Stage III Rectal Cancer AJCC v7 / Stage IIIA Colon Cancer AJCC v7 / Stage IIIA Rectal Cancer AJCC v7 / Stage IIIB Colon Cancer AJCC v7 / Stage IIIB Rectal Cancer AJCC v7 / Stage IIIC Colon Cancer AJCC v7 / Stage IIIC Rectal Cancer AJCC v7 / Stage IV Colon Cancer AJCC v7 / Stage IV Rectal Cancer AJCC v7 / Stage IVA Colon Cancer AJCC v7 / Stage IVA Rectal Cancer AJCC v7 / Stage IVB Colon Cancer AJCC v7 / Stage IVB Rectal Cancer AJCC v71
2RecruitingTreatmentColorectal Adenocarcinoma Metastatic to the Liver1
2RecruitingTreatmentColorectal Cancers4
2RecruitingTreatmentDrug Therapy / Radiations / Rectal Neoplasms1
2RecruitingTreatmentEwing's Sarcoma (ES)2
2RecruitingTreatmentEwing's Tumor Metastatic1
2RecruitingTreatmentFirst Line Metastatic Colorectal Cancer1
2RecruitingTreatmentGastric Adenocarcinoma / Gastro-esophageal Junction Adenocarcinoma1
2RecruitingTreatmentHigh Grade Malignant Neuroendocrine Carcinoma (Diagnosis)1
2RecruitingTreatmentIncurable Colorectal Cancer / RAS-wild-type1
2RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
2RecruitingTreatmentLung Neoplasms, Non-Small Cell Lung Cancer1
2RecruitingTreatmentMalignant Neoplasm of Colon1
2RecruitingTreatmentMalignant Neoplasm of Pancreas2
2RecruitingTreatmentMetastatic Colon Cancer / Mucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IV Rectal Cancer1
2RecruitingTreatmentMetastatic Colorectal Cancers9
2RecruitingTreatmentMetastatic Gastric Adenocarcinoma1
2RecruitingTreatmentNeoplasms, Colorectal1
2RecruitingTreatmentNeuroblastomas2
2RecruitingTreatmentNeuroendocrine Carcinomas1
2RecruitingTreatmentNewly Diagnosed Ewing Sarcoma1
2RecruitingTreatmentPancreatic Cancer Metastatic1
2RecruitingTreatmentPancreatic Ductal Carcinoma1
2RecruitingTreatmentPancreatic Metastatic Cancer / Toxicity1
2RecruitingTreatmentPediatric Solid Tumors1
2RecruitingTreatmentPinealoblastoma1
2RecruitingTreatmentPreviously Treated Metastatic Colorectal Cancer1
2RecruitingTreatmentRectal Carcinoma1
2RecruitingTreatmentRecurrent Neuroblastoma1
2RecruitingTreatmentResectable Pancreatic Ductal Adenocarcinoma1
2RecruitingTreatmentRhabdomyosarcomas1
2RecruitingTreatmentSmall Cell Lung Carcinoma1
2RecruitingTreatmentSquamous Cell Carcinoma of Esophagus2
2RecruitingTreatmentStomach Neoplasms2
2SuspendedTreatmentMalignant Neoplasm of Stomach1
2SuspendedTreatmentNeoplasms, Colorectal1
2TerminatedNot AvailableColorectal Cancers1
2TerminatedDiagnosticAstrocytomas / Gliomas / Oligodendrogliomas1
2TerminatedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Metastatic Colon Cancer / Mucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IV Rectal Cancer1
2TerminatedTreatmentAdenocarcinoma of the Pancreas1
2TerminatedTreatmentAdenocarcinoma of the Pancreas / Poorly Differentiated Malignant Neoplasm / Resectable Pancreatic Cancers / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer / Undifferentiated Pancreatic Carcinoma1
2TerminatedTreatmentAdenocarcinomas / Malignant Neoplasm of Colon1
2TerminatedTreatmentAppendix Tumors / Colon Tumors / Endocrine Tumors / Peritoneum Tumors / Rectum Tumors1
2TerminatedTreatmentBone Cancer / Ewing's Sarcoma (ES)1
2TerminatedTreatmentBorderline Resectable Pancreatic Cancer1
2TerminatedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2TerminatedTreatmentCancer, Breast1
2TerminatedTreatmentCervical Cancers1
2TerminatedTreatmentColorectal Adenocarcinoma / Colorectal Cancers1
2TerminatedTreatmentColorectal Cancers11
2TerminatedTreatmentDiarrhea / Neoplasms, Colorectal1
2TerminatedTreatmentDrug Therapy, Combination / Neoplasms, Colorectal / Secondary1
2TerminatedTreatmentEsophageal Cancers2
2TerminatedTreatmentEsophageal Cancers / Gastric Adenocarcinoma / Malignant Neoplasm of Stomach1
2TerminatedTreatmentEsophageal Cancers / Gastrooesophageal Cancer1
2TerminatedTreatmentGlioblastoma Multiforme (GBM)1
2TerminatedTreatmentGlioblastoma Multiforme (GBM) / Gliosarcoma / Malignant Gliomas1
2TerminatedTreatmentHepatic Metastases / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2TerminatedTreatmentHigh-Grade Gliomas1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2TerminatedTreatmentMalignant Glioma of Brain1
2TerminatedTreatmentMalignant Neoplasm of Colon / Rectal Carcinoma1
2TerminatedTreatmentMalignant Neoplasm of Pancreas / Pancreatic Carcinoma Non-resectable1
2TerminatedTreatmentMetastases / Neoplasms, Colorectal1
2TerminatedTreatmentMetastatic Colorectal Cancers6
2TerminatedTreatmentNeoplasms Metastasis / Neoplasms, Colorectal1
2TerminatedTreatmentNeoplasms, Colorectal1
2TerminatedTreatmentNeuroblastomas1
2TerminatedTreatmentOesophageal Carcinoma1
2TerminatedTreatmentRectal Carcinoma1
2TerminatedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentRenal Cancers1
2TerminatedTreatmentSarcomas1
2Unknown StatusBasic ScienceMetastatic Colorectal Cancers1
2Unknown StatusDiagnosticRecurrent Malignant Gliomas1
2Unknown StatusTreatmentAdvanced Esophageal Squamous Carcinoma1
2Unknown StatusTreatmentBiliary Tract Cancer1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Recurrent Glioblastoma Multiforme1
2Unknown StatusTreatmentCarcinoma, Colorectal1
2Unknown StatusTreatmentColonic Neoplasms1
2Unknown StatusTreatmentColorecal Neoplasms / Secondary1
2Unknown StatusTreatmentColorectal Cancers9
2Unknown StatusTreatmentColorectal Cancers / Metastatic Cancers2
2Unknown StatusTreatmentEsophageal Cancers1
2Unknown StatusTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2Unknown StatusTreatmentHepatic Lesions / Hepatic Metastases / Metastatic Colorectal Cancers1
2Unknown StatusTreatmentLiver Cancer1
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
2Unknown StatusTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2Unknown StatusTreatmentLung Cancers2
2Unknown StatusTreatmentMalignant Neoplasm of Stomach2
2Unknown StatusTreatmentMetastatic Colorectal Cancers2
2Unknown StatusTreatmentMetastatic / Second-Line / Stomach Neoplasms1
2Unknown StatusTreatmentNeoadjuvant Therapy / Rectal Neoplasms1
2Unknown StatusTreatmentNeoadjuvant Treatment / Rectal Neoplasms1
2Unknown StatusTreatmentNeoplasms, Brain1
2Unknown StatusTreatmentSarcomas2
2Unknown StatusTreatmentSmall Cell Carcinoma of Lung1
2Unknown StatusTreatmentStomach Neoplasms1
2WithdrawnTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum1
2WithdrawnTreatmentBiliary Tract Cancer1
2WithdrawnTreatmentColorectal Cancers2
2WithdrawnTreatmentColorectal Cancers / Malignant Neoplasm of Colon1
2WithdrawnTreatmentColorectal Cancers / Metastatic Cancers1
2WithdrawnTreatmentLung Cancers1
2WithdrawnTreatmentMalignant Gliomas1
2WithdrawnTreatmentMetastatic Colorectal Cancers2
2, 3CompletedDiagnosticColorectal Cancers1
2, 3CompletedTreatmentColorectal Cancers2
2, 3CompletedTreatmentEsophageal Cancers1
2, 3CompletedTreatmentMalignant Neoplasm of Pancreas1
2, 3CompletedTreatmentMalignant Neoplasm of Stomach1
2, 3CompletedTreatmentMetastatic Colorectal Cancers2
2, 3RecruitingTreatmentChildhood Hepatocellular Carcinoma / Childhood Malignant Liver Neoplasm / Elevated Alpha-Fetoprotein / Hepatoblastomas / SMARCB1 Gene Mutation1
2, 3RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
2, 3RecruitingTreatmentMalignant Neoplasm of Pancreas1
2, 3RecruitingTreatmentResectable Prancreas Carcinoma1
2, 3Unknown StatusTreatmentGlioblastomas1
2, 3Unknown StatusTreatmentMalignant Neoplasm of Pancreas1
2, 3Unknown StatusTreatmentStage IIIB, IV, Recurrent, and Metastatic Breast Cancer1
3Active Not RecruitingTreatmentAdult Malignant Mesenchymoma / Adult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Botryoid-Type Embryonal Rhabdomyosarcoma / Childhood Embryonal Rhabdomyosarcoma / Childhood Malignant Mesenchymoma / Non-Metastatic Childhood Soft Tissue Sarcoma / Stage I Adult Soft Tissue Sarcoma / Stage II Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
3Active Not RecruitingTreatmentDigestive System Neoplasms / Intestinal Neoplasms / Neoplasms Metastasis / Neoplasms, Colorectal / Neoplasms, Gastrointestinal1
3Active Not RecruitingTreatmentEsophagogastric Junction Carcinoma / Oesophageal Carcinoma1
3Active Not RecruitingTreatmentGastric Cancer Third Line / Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma1
3Active Not RecruitingTreatmentGastroesophageal Junction Cancer / Malignant Neoplasm of Stomach1
3Active Not RecruitingTreatmentLocally Advanced Malignant Neoplasm / Malignant Neoplasm of Pancreas / Pancreatic Carcinoma Non-resectable1
3Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
3Active Not RecruitingTreatmentPRETEXT Stage 1 Hepatoblastoma / PRETEXT Stage 2 Hepatoblastoma / PRETEXT Stage 3 Hepatoblastoma / PRETEXT Stage 4 Hepatoblastoma1
3Active Not RecruitingTreatmentSarcomas1
3CompletedNot AvailableNeoplasms Metastasis / Stomach Neoplasms1
3CompletedTreatmentAdenocarcinoma of the Colon / Stage III Colon Cancer2
3CompletedTreatmentAdenocarcinoma of the Stomach / Adenocarcinomas of the Gastroesophageal Junction1
3CompletedTreatmentAdvanced Colorectal Cancer1
3CompletedTreatmentColorectal Cancers13
3CompletedTreatmentColorectal Cancers / Metastasis1
3CompletedTreatmentColorectal Cancers / Metastatic Cancers2
3CompletedTreatmentEpidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer1
3CompletedTreatmentInoperable Gastric Cancer1
3CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
3CompletedTreatmentLung Cancers1
3CompletedTreatmentMalignant Neoplasm of Stomach1
3CompletedTreatmentMetastatic Colorectal Cancers4
3CompletedTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
3CompletedTreatmentNeoplasms Metastasis / Neoplasms, Colorectal1
3CompletedTreatmentPancreatic Cancer Metastatic1
3CompletedTreatmentSmall Cell Lung Carcinoma1
3CompletedTreatmentTumors, Solid1
3CompletedTreatmentUnknown Primary Neoplasms1
3Not Yet RecruitingTreatmentCarcinoma, Colorectal1
3Not Yet RecruitingTreatmentColorectal Cancers1
3Not Yet RecruitingTreatmentEwing Family of Tumors / Ewing's Sarcoma (ES) / Ewing's Tumor Metastatic / Metastatic Ewing's Sarcoma1
3RecruitingTreatmentBRAF V600E-mutant Metastatic Colorectal Cancer1
3RecruitingTreatmentBotryoid-Type Embryonal Rhabdomyosarcoma / Rhabdomyosarcoma, Alveolar / Rhabdomyosarcoma, Embryonal / Rhabdomyosarcomas / Sclerosing Rhabdomyosarcoma / Spindle Cell Rhabdomyosarcoma / Untreated Childhood Rhabdomyosarcoma1
3RecruitingTreatmentCarcinoma NOS / Malignant Neoplasm of Pancreas1
3RecruitingTreatmentChemotherapeutic Toxicity / Chemotherapy Effect / Stomach Neoplasms1
3RecruitingTreatmentColon Cancer (High-risk Stage III; pT4N1 or pT1 to 4 N2)1
3RecruitingTreatmentColorectal Cancers1
3RecruitingTreatmentDigestive System Neoplasms / Intestinal Neoplasms / Neoplasms Metastasis / Neoplasms, Colorectal / Neoplasms, Gastrointestinal1
3RecruitingTreatmentEffects of Chemotherapy / General Surgery / Local Neoplasm Recurrences / Metastasis / Neoplasms, Colorectal1
3RecruitingTreatmentHepatoblastomas / Hepatocellular,Carcinoma1
3RecruitingTreatmentLocally Advanced Pancreatic Cancer / Pancreatic Cancer Metastatic1
3RecruitingTreatmentLocally Advanced Rectal Cancer1
3RecruitingTreatmentMalignant Neoplasm of Pancreas1
3RecruitingTreatmentMetastatic Colorectal Cancers3
3RecruitingTreatmentNeoplasms, Esophageal1
3RecruitingTreatmentOesophageal Carcinoma1
3RecruitingTreatmentPreviously Treated Metastatic Colorectal Cancer1
3SuspendedTreatmentBrain Cancer / Choroid Plexus Tumors1
3SuspendedTreatmentMetastatic Colorectal Cancers1
3TerminatedSupportive CareColorectal Cancers / Diarrhea1
3TerminatedTreatmentColorectal Cancers2
3TerminatedTreatmentMucinous Adenocarcinoma of the Rectum / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Rectum / Stage IIA Rectal Cancer / Stage IIB Rectal Cancer / Stage IIC Rectal Cancer / Stage IIIA Rectal Cancer / Stage IIIB Rectal Cancer / Stage IIIC Rectal Cancer / Stage IVA Rectal Cancer / Stage IVB Rectal Cancer1
3TerminatedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
3Unknown StatusTreatmentColorectal Cancers7
3Unknown StatusTreatmentColorectal Cancers / Neoplasms Metastasis1
3Unknown StatusTreatmentMalignant Neoplasm of Stomach1
3Unknown StatusTreatmentMetastatic Breast Cancer (MBC)1
3Unknown StatusTreatmentMetastatic Colorectal Cancers1
4Active Not RecruitingTreatmentMalignant Neoplasm of Stomach / Stage IV Colorectal Cancer1
4CompletedTreatmentColorectal Cancers1
4CompletedTreatmentColorectal Cancers / Neoplasms, Colorectal1
4CompletedTreatmentMetastatic Colorectal Cancers1
4CompletedTreatmentTumors, Solid1
4CompletedTreatmentUpper Gastrointestinal Tumours1
4RecruitingTreatmentAdenocarcinoma Of Esophagus / Gastric Adenocarcinoma / Stage IIB Gastric Cancer / Stage IIIA Esophageal Adenocarcinoma / Stage IIIA Gastric Cancer / Stage IIIB Esophageal Adenocarcinoma / Stage IIIB Gastric Cancer / Stage IIIC Esophageal Adenocarcinoma / Stage IIIC Gastric Cancer1
4RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
4RecruitingTreatmentMalignant Neoplasm of Stomach1
Not AvailableActive Not RecruitingTreatmentLocalized Pancreas Cancer / Malignant Neoplasm of Pancreas / Non-metastatic Pancreas Cancer1
Not AvailableActive Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
Not AvailableActive Not RecruitingTreatmentPancreatic Ductal Adenocarcinoma (PDAC)1
Not AvailableCompletedNot AvailableBiomarkers / Chemotherapy Effect / Metastatic Colorectal Cancers1
Not AvailableCompletedNot AvailableMetastatic Colorectal Cancers1
Not AvailableCompletedTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer1
Not AvailableCompletedTreatmentMetastatic Colorectal Cancers1
Not AvailableCompletedTreatmentRectal Carcinoma1
Not AvailableNot Yet RecruitingTreatmentAdvanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction1
Not AvailableRecruitingNot AvailablePancreatic Cancer Metastatic1
Not AvailableRecruitingTreatmentMetastatic Colorectal Cancers1
Not AvailableTerminatedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
Not AvailableUnknown StatusNot AvailableCancer of the Ovary / Cervical Cancers / Gastric Cancer (Inoperable and Recurrent) / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC)1
Not AvailableUnknown StatusBasic ScienceNeoplasms, Colorectal / Secondary1
Not AvailableWithdrawnTreatmentCentral Nervous System Metastases / Male Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
Not AvailableWithdrawnTreatmentColorectal Cancers1
Not AvailableWithdrawnTreatmentColorectal Cancers / Hepatic Metastases1
Not AvailableWithdrawnTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1

Pharmacoeconomics

Manufacturers
  • Pfizer inc
  • Accord healthcare inc
  • Actavis totowa llc
  • Akorn inc
  • App pharmaceuticals
  • Bedford laboratories
  • Dr reddys laboratories ltd
  • Ebewe pharma ges mbh nfg kg
  • Fresenius kabi oncology plc
  • Hospira inc
  • Pharmaforce inc
  • Pliva lachema as
  • Sandoz inc
  • Sun pharma global inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
Packagers
  • Actavis Group
  • APP Pharmaceuticals
  • Barr Pharmaceuticals
  • Baxter International Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Cipla Ltd.
  • Ebewe Pharma
  • Fresenius Kabi AB
  • Greenstone LLC
  • Hospira Inc.
  • Jiangsu Hengrui Medicine Co. Ltd.
  • Pfizer Inc.
  • Pharmacia Inc.
  • Pliva Inc.
  • Sagent Pharmaceuticals
  • Sandoz
  • SC Sindan Pharma SRL
  • Sicor Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
SolutionIntravenous20 mg
InjectionIntravenous100 mg/5mL
InjectionIntravenous20 mg/mL
InjectionIntravenous40 mg/2mL
Injection, solutionIntravenous100 mg/5mL
Injection, solutionIntravenous20 mg/mL
Injection, solutionIntravenous40 mg/2mL
InjectionIntravenous4.3 mg/mL
Injection, powder, for solutionIntravenous4.3 mg/mL
Prices
Unit descriptionCostUnit
Irinotecan hcl 40 mg/2 ml inj138.07USD ml
Camptosar 20 mg/ml vial36.0USD ml
Irinotecan hcl 40 mg/2 ml vial22.2USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2202531No2005-05-032015-10-11Canada
CA2294031No2005-01-182018-07-27Canada
US6403569Yes2000-10-282020-10-28Us
US6794370Yes2000-11-012020-11-01Us
US8703181No2005-05-022025-05-02Us
US8329213No2005-05-022025-05-02Us
US8992970No2005-05-022025-05-02Us
US8147867No2008-08-292028-08-29Us
US9364473No2013-06-122033-06-12Us
US9492442No2013-06-122033-06-12Us
US9339497No2013-06-122033-06-12Us
US9452162No2013-06-122033-06-12Us
US9717724No2013-06-122033-06-12Us
US9730891No2005-05-022025-05-02Us
US9724303No2005-05-022025-05-02Us
US9782349No2005-05-022025-05-02Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)222-223 °CNot Available
water solubilitySolubleNot Available
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.107 mg/mLALOGPS
logP3.94ALOGPS
logP2.78ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)11.71ChemAxon
pKa (Strongest Basic)9.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area112.51 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity161.33 m3·mol-1ChemAxon
Polarizability65.27 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.969
Blood Brain Barrier+0.6284
Caco-2 permeable-0.6065
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor IInhibitor0.7092
P-glycoprotein inhibitor IINon-inhibitor0.5337
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8174
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.8564
CYP450 2C9 inhibitorNon-inhibitor0.7377
CYP450 2D6 inhibitorNon-inhibitor0.7779
CYP450 2C19 inhibitorNon-inhibitor0.6625
CYP450 3A4 inhibitorInhibitor0.8295
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5081
Ames testNon AMES toxic0.6977
CarcinogenicityNon-carcinogens0.8045
BiodegradationNot ready biodegradable0.9956
Rat acute toxicity2.7960 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9457
hERG inhibition (predictor II)Inhibitor0.5413
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0091000000-b15811b1af58e71b3ec6
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0101190000-eed1a0e57a719811aa8e

Taxonomy

Description
This compound belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring).
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Camptothecins
Sub Class
Not Available
Direct Parent
Camptothecins
Alternative Parents
Quinolines and derivatives / Pyranopyridines / Piperidinecarboxylic acids / Aminopiperidines / Pyridinones / Benzenoids / Tertiary alcohols / Carbamate esters / Heteroaromatic compounds / Trialkylamines
show 11 more
Substituents
Camptothecin / Pyranopyridine / Quinoline / Piperidinecarboxylic acid / 4-aminopiperidine / Pyridinone / Piperidine / Pyridine / Benzenoid / Carbamic acid ester
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
pyranoindolizinoquinoline (CHEBI:80630) / Quinoline alkaloids (C16641)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Poly(a) rna binding
Specific Function
Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a singl...
Gene Name
TOP1
Uniprot ID
P11387
Uniprot Name
DNA topoisomerase 1
Molecular Weight
90725.19 Da
References
  1. Yoshikawa M, Ikegami Y, Hayasaka S, Ishii K, Ito A, Sano K, Suzuki T, Togawa T, Yoshida H, Soda H, Oka M, Kohno S, Sawada S, Ishikawa T, Tanabe S: Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer. 2004 Jul 20;110(6):921-7. [PubMed:15170677]
  2. Yoshikawa M, Ikegami Y, Sano K, Yoshida H, Mitomo H, Sawada S, Ishikawa T: Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J Exp Ther Oncol. 2004 Apr;4(1):25-35. [PubMed:15255290]
  3. Yang X, Hu Z, Chan SY, Chan E, Goh BC, Duan W, Zhou S: Novel agents that potentially inhibit irinotecan-induced diarrhea. Curr Med Chem. 2005;12(11):1343-58. [PubMed:15975002]
  4. Nakagawa H, Saito H, Ikegami Y, Aida-Hyugaji S, Sawada S, Ishikawa T: Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. Cancer Lett. 2006 Mar 8;234(1):81-9. Epub 2005 Nov 23. [PubMed:16309825]
  5. Ishikawa T, Ikegami Y, Sano K, Nakagawa H, Sawada S: Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells. Curr Pharm Des. 2006;12(3):313-25. [PubMed:16454746]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Ramesh M, Ahlawat P, Srinivas NR: Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23. doi: 10.1002/bmc.1345. [PubMed:19852077]
  8. Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997 Oct;33(4):245-59. [PubMed:9342501]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Releases the supercoiling and torsional tension of DNA introduced during duplication of mitochondrial DNA by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-str...
Gene Name
TOP1MT
Uniprot ID
Q969P6
Uniprot Name
DNA topoisomerase I, mitochondrial
Molecular Weight
69871.39 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Yoshikawa M, Ikegami Y, Hayasaka S, Ishii K, Ito A, Sano K, Suzuki T, Togawa T, Yoshida H, Soda H, Oka M, Kohno S, Sawada S, Ishikawa T, Tanabe S: Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer. 2004 Jul 20;110(6):921-7. [PubMed:15170677]
  4. Yoshikawa M, Ikegami Y, Sano K, Yoshida H, Mitomo H, Sawada S, Ishikawa T: Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J Exp Ther Oncol. 2004 Apr;4(1):25-35. [PubMed:15255290]
  5. Yang X, Hu Z, Chan SY, Chan E, Goh BC, Duan W, Zhou S: Novel agents that potentially inhibit irinotecan-induced diarrhea. Curr Med Chem. 2005;12(11):1343-58. [PubMed:15975002]
  6. Nakagawa H, Saito H, Ikegami Y, Aida-Hyugaji S, Sawada S, Ishikawa T: Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. Cancer Lett. 2006 Mar 8;234(1):81-9. Epub 2005 Nov 23. [PubMed:16309825]
  7. Ishikawa T, Ikegami Y, Sano K, Nakagawa H, Sawada S: Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells. Curr Pharm Des. 2006;12(3):313-25. [PubMed:16454746]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  9. Ramesh M, Ahlawat P, Srinivas NR: Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23. doi: 10.1002/bmc.1345. [PubMed:19852077]
  10. Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997 Oct;33(4):245-59. [PubMed:9342501]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Ramesh M, Ahlawat P, Srinivas NR: Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23. doi: 10.1002/bmc.1345. [PubMed:19852077]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Kuhn JG: Pharmacology of irinotecan. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):39-42. [PubMed:9726089]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Kuhn JG: Pharmacology of irinotecan. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):39-42. [PubMed:9726089]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997 Oct;33(4):245-59. [PubMed:9342501]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Triglyceride lipase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acy...
Gene Name
CES1
Uniprot ID
P23141
Uniprot Name
Liver carboxylesterase 1
Molecular Weight
62520.62 Da
References
  1. Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997 Oct;33(4):245-59. [PubMed:9342501]
  2. Ramesh M, Ahlawat P, Srinivas NR: Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23. doi: 10.1002/bmc.1345. [PubMed:19852077]
  3. Kuhn JG: Pharmacology of irinotecan. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):39-42. [PubMed:9726089]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Methylumbelliferyl-acetate deacetylase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Shows high catalytic efficiency for hydrolysis of cocaine, 4-methylumbelliferyl acetate, heroin and ...
Gene Name
CES2
Uniprot ID
O00748
Uniprot Name
Cocaine esterase
Molecular Weight
61806.41 Da
References
  1. Sanghani SP, Quinney SK, Fredenburg TB, Davis WI, Murry DJ, Bosron WF: Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos. 2004 May;32(5):505-11. [PubMed:15100172]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Link [Link]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Toxin transporter activity
Specific Function
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name
SLC22A3
Uniprot ID
O75751
Uniprot Name
Solute carrier family 22 member 3
Molecular Weight
61279.485 Da
References
  1. Shnitsar V, Eckardt R, Gupta S, Grottker J, Muller GA, Koepsell H, Burckhardt G, Hagos Y: Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009 Feb 15;69(4):1494-501. doi: 10.1158/0008-5472.CAN-08-2483. Epub 2009 Feb 3. [PubMed:19190342]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos. 2005 Mar;33(3):434-9. Epub 2004 Dec 17. [PubMed:15608127]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Chen ZS, Furukawa T, Sumizawa T, Ono K, Ueda K, Seto K, Akiyama SI: ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8. [PubMed:10220571]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72. [PubMed:12488537]
  2. Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RC, de Jong LA, Pluim D, Beijnen JH, Schellens JH: Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res. 2001 Apr;7(4):935-41. [PubMed:11309344]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Kroetz DL: Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. J Clin Oncol. 2006 Sep 10;24(26):4225-7. Epub 2006 Aug 8. [PubMed:16895999]
  2. Han JY, Lim HS, Park YH, Lee SY, Lee JS: Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009 Jan;63(1):115-20. doi: 10.1016/j.lungcan.2007.12.003. Epub 2008 Jan 24. [PubMed:18221820]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Kroetz DL: Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. J Clin Oncol. 2006 Sep 10;24(26):4225-7. Epub 2006 Aug 8. [PubMed:16895999]
  2. Han JY, Lim HS, Park YH, Lee SY, Lee JS: Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009 Jan;63(1):115-20. doi: 10.1016/j.lungcan.2007.12.003. Epub 2008 Jan 24. [PubMed:18221820]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:44